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1 Introduction 
1.1 Gene therapy 
Gene therapy, as first proposed 1972 by Friedman and Roblin (1), aims at the 
delivery of nucleic acids (DNA or RNA) into target cells in order to cure patients 
suffering from different diseases. The transferred nucleic acids are mostly used to 
turn on or restore a gene function (‘gain of function’). A relatively new field in gene 
therapy applies nucleic acids to suppress specific gene functions (‘loss of function’) 
by turning off genes with antisense oligonucleotides or double-stranded small 
interfering RNA (siRNA).  
Although gene therapy has not yet been established as standard treatment, it was 
already applied in various clinical studies, e.g. in the field of cancer therapy (most 
clinical trials), monogenic diseases (Hemophilia A and B, cystic fibrosis, severe 
combined immunodeficiency syndrome (SCID)), infectious diseases, vascular 
diseases, or DNA vaccination (2). Gene therapy may hold the potential to 
revolutionize modern molecular medicine, provided that appropriate nucleic acid 
delivery systems (‘vector systems’) are available.  
1.2 Viral and nonviral vectors 
Current vectors can be divided into two major groups, namely viral vectors derived 
from natural viruses and nonviral, synthetically manufactured vectors.  
1.2.1 Viral vectors 
Since it is the nature of viruses to deliver their genes into host cells, they present 
good candidates for the development of effective gene delivery. Natural evolution, 
however, optimized them for infecting and replicating their genome in host cells, but 
not necessarily for survival of the transduced cells or maintenance of the expressed 
genes. Nevertheless, replication-defective viruses, where viral genes were partly 
replaced by therapeutic genes, were historically the first generation of ‘viral vectors’ 
applied in gene therapy. 
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Retroviral vectors and adenoviral vectors have been most commonly used in clinical 
trials (2). Other viruses that were used to develop viral vectors include adeno-
associated virus (AAV), herpes virus, pox virus, and more recently lentivirus. Viruses 
in general are highly efficient regarding cellular uptake and intracellular delivery of 
therapeutic genes to the nucleus. Therefore, few viral particles are sufficient for the 
transduction of cells.  
Gene transfer activity of viral vectors also strongly depends on the type of virus used 
for transduction. Murine retroviral vectors, for example, are very useful for ex vivo 
gene transfer because of their high efficiency to integrate into the host cell genome. 
In particular, they have been optimized for gene transfer into hematopoietic stem 
cells. The gene therapy of human SCID-X1 can be regarded as the first success 
story in gene therapy (3). All ten children treated in this trial were cured of the 
immunodeficiency symptoms. The therapy, however, was associated with the 
incidence of leukemia in two of the treated children, and subsequent chemotherapy 
was required. Insertional oncogenesis by the retroviral vector was identified as the 
reason for this severe side effect, highlighting a serious risk of such stably but 
randomly integrating viral vector systems that may cause fatal long term changes in 
gene expression in addition to the desired therapeutic effect. 
Adenoviral vectors do not bear the risk of insertional oncogenesis, since these 
vectors do not integrate into the host genome. Moreover, adenoviral vectors can 
efficiently transfer genes into both dividing and non-dividing cells. However, natural 
immunity against adenovirus (the virus causes human respiratory diseases) and 
acute inflammatory and immune responses limit clinical application to few areas such 
as localized cancer gene therapy. Systemic administration of a large amount of 
adenovirus (e.g. into the liver) may cause serious side effects including 
thrombocytopenia, intravascular coagulation and multiple organ system failure that 
even caused the death of one patient (4;5). Recent approaches to improve viral 
vector safety included strategies to reduce the number of remaining adenoviral 
genes, from ‘first generation’ adenoviruses, where only one early gene segment was 
removed, to so-called high-capacity ‘gutless’ adenoviruses, where all viral genes 
have been replaced (6). Unfortunately, even high-capacity ‘gutless’ adenoviruses 
triggered inflammatory and immune responses (6;7). 
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Such host responses are obviously independent of the type of virus and of viral gene 
expression but they are rather attributed to the viral infection process and to viral 
proteins in the vector particle. Inflammatory and immune host responses to viruses 
therefore exclude repeated in vivo administration of viral vectors in general. 
1.2.2 Nonviral vectors 
Nonviral vectors are more flexible in terms of type and size of the delivered nucleic 
acids (8). A broad range of nucleic acids from small double-stranded RNA for 
interfering with gene expression up to large artificial chromosomes can be used for 
transfection. Both the nucleic acids and the carrier molecules can be produced at 
large scale with rather low cost. Their synthetic design allows high flexibility of the 
formulation that can be easily modified by diverse chemical reactions and physical 
interactions. The great advantage of nonviral vectors is their low immunogenicity, 
since synthetic vectors present far less or no immunogenic proteins or peptides in 
comparison to viral vectors. Nonviral vectors are usually based on chemically defined 
lipids or polycations and can be generated protein-free or using non-immunogenic 
human or humanized proteins and peptides only.  
An obvious weakness of nonviral vectors is their low efficiency in intracellular nucleic 
acid delivery which currently is partly compensated by administration of large 
amounts of the vectors. Direct injection of mg quantities of ‘naked’ DNA is usually 
well tolerated but still only yields very low levels of transfection. Nevertheless, 
application of naked DNA led to protein expression that was sufficient for triggering 
immune responses and was used for human DNA vaccination trials (9). To enhance 
the delivery of naked DNA, a series of strategies have been applied that used 
physical forces, such as electric pulses, mechanical forces, or hydrodynamic 
pressure. Electroporation, for example, enhanced transgene expression by two or 
three orders of magnitude and was sufficient to stimulate strong immune responses 
in DNA vaccine applications (10).  
Since degradation of naked DNA by serum nucleases limits systemic administration, 
different complex-based gene transfer vectors have been developed in order to 
enhance the stability of the delivered nucleic acids. In these vectors, the nucleic 
acids are condensed with cationic lipids or polycations to generate complexes called 
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‘lipoplexes’ or ‘polyplexes’, respectively. The cationic agents bind to DNA or RNA due 
to electrostatic interactions and form particles of nanometer range. Such compaction 
protects the nucleic acids from enzymatic degradation. Cationic lipids usually consist 
of a cationic headgroup for electrostatic binding to the nucleic acid and a lipophilic 
tail, which enables the generation of a nucleic acid/lipid complex (for review see 
(11)). Polycationic carriers are naturally occurring proteins like histones or 
protamines, chemically synthesized polyaminoacids, e.g. polylysine and polyarginine, 
or other polycationic polymers (for review see (12) and (13)). More recently, 
polyethylenimine (PEI) has been described as an useful carrier for the condensation 
of DNA, and it has become one of the most efficient reagents for gene delivery into 
cells (for review see (14)).  
1.2.3 Gene delivery with PEI polyplexes 
Jean-Paul Behr and colleagues were the first to report the successful use of PEI for 
the delivery of DNA and oligonucleotides (15). PEI polymers can be synthesized with 
a linear or a branched topology (Fig. 1) and are available in a wide range of 
molecular weights (16). 
Fig. 1 Structure of linear and branched PEI 
PEI is the organic macromolecule with the highest density of protonable amine 
functions and is therefore ideal to condense nucleic acids into particles of nanometer 
range (17). The amino groups allow easy chemical modification, and different 
biologically active moieties such as cell targeting ligands or compounds promoting 
intracellular delivery have been coupled to PEI (18). Since these compounds mimic 
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viral delivery functions, such complex vector systems carrying multiple functional 
domains have been termed ‘artificial viruses’ (18).  
The condensation process of DNA with the polycation PEI has been studied 
extensively. The particle size of DNA/PEI complexes depends on the molar ratio of 
PEI nitrogen to DNA phosphate (N/P ratio) and on the present salt concentration. 
Small individual particles are formed at low salt concentration (< 50 mM NaCl) and/or 
N/P ratios above 5, whereas formation of large aggregated particles is observed in 
the presence of salt (> 50 mM NaCl) at lower N/P ratios (19;20). The net positive 
surface charge and an excess of free PEI during complex formation can prevent 
aggregation by repulsion of positive charges, whereas an increase in salt 
concentration reduces the hydration layer around the particles and promotes particle 
aggregation.  
1.2.4 Barriers to gene transfer with PEI polyplexes 
For successful gene delivery, gene vectors have to overcome a number of 
extracellular and intracellular barriers until the carried nucleic acids reach their final 
destination, the nucleus. The in vivo delivery of viral vectors is strongly hampered by 
extracellular barriers. For example, systemic targeting of viral vectors towards the 
desired tissue is difficult to realize due to host immune responses that trigger viral 
clearance. Viral vectors, however, are very efficient in overcoming intracellular 
barriers such as internalization into the host cell and delivery of the therapeutic gene 
towards the nucleus. In contrast, poor intracellular delivery of the carried nucleic acid 
remains the major barrier to effective gene transfer with nonviral vectors. The 
following section gives an overview of barriers to nonviral vectors in general and 
gives examples of how these barriers can be overcome using PEI polyplexes. 
1.2.4.1 Extracellular barriers 
As explained above, many nonviral vectors are generated using positively charged 
lipids or polycations resulting in particles with a net positive surface charge. Although 
positively charged vectors like PEI polyplexes expose high gene transfer activity in 
vitro (for example see (19;20)), systemic administration of such particles is rather 
restricted. After tail vein injection of different positively charged lipo- and polyplexes 
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into mice, complexes were rapidly cleared from the circulation and mainly 
accumulated in the lung. Gene expression levels found in the lung were several log 
units higher than in any other organ (for example see (21)). In addition, gene transfer 
at effective DNA doses was associated with acute toxicity. Ex vivo experiments 
revealed that positively charged polyplexes induced aggregation of erythrocytes. It 
was proposed that both unspecific lung expression and toxicity were attributed to the 
aggregation of initially small polyplexes with blood components and their subsequent 
entrapment in the lung capillary bed (22). Obviously, the positive surface charge of 
complexes mediates unspecific interactions with non-target cells and blood-
components resulting in the observed systemic side effects. These adverse effects 
can be overcome by ‘shielding’ of the positive surface charge of the vectors with 
hydrophilic polymers like polyethylene glycol (PEG). PEGylation of PEI polyplexes 
prevented erythrocyte aggregation, enhanced systemic circulation time and reduced 
toxicity of polyplexes (21;23). Shielding with PEG, however, also reduces the overall 
transfection efficiency because of reduced interaction with cell membranes of all cells 
including the target cells.  
In order to direct the shielded particles towards the desired tissue and to promote 
specific uptake into target cells, different targeting ligands have been incorporated 
into the vectors. These ligands recognize specific cellular receptors present on the 
plasma membrane of the target cells. Ligands that have been used to promote 
targeted delivery of vectors include small chemical compounds (24), carbohydrates 
(25), peptide ligands (26), growth factors and proteins (27-29), or antibodies (30;31). 
More details of applied targeting ligands are summarized in (32) and (33). For 
example, systemic targeting of PEI polyplexes towards tumors was demonstrated 
using the transferrin receptor (21;29;34) or the epidermal growth factor (EGF) 
receptor (28) as targets. Targeting efficiencies, however, remain to be improved, 
because transfection efficiencies of shielded and targeted nonviral vectors are rather 
poor both in vitro and in vivo. This low transfection efficiencies are mainly attributed 
to different intracellular barriers within the transfection process.  
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1.2.4.2 Intracellular barriers 
After cellular association of nonviral vectors to the target cells, particles are 
internalized by receptor-mediated endocytosis, macropinocytosis, phagocytosis or 
related processes (35-37). For successful transgene expression, several intracellular 
barriers then have to be overcome. Fig. 2 illustrates cellular uptake of artificial virus-
like PEI polyplexes carrying multiple functional domains to overcome these barriers. 
Fig. 2 Cellular uptake of artificial virus-like PEI polyplexes. PEG-shielded and receptor-targeted PEI 
polyplexes are mainly internalized into cells by receptor-mediated endocytosis after association of 
polyplex-ligands to receptors present on the plasma membrane. Internalized particles are captured in 
intracellular vesicles such as endosomes. For effective gene delivery, polyplexes need to escape from 
endosomes by endosomal release, and the released particles and/or the carried nucleic acid need to 
traffic towards the nucleus, enter the nucleus and expose the DNA to the cell’s transcription 
machinery. Different functional domains incorporated into the polyplexes may help to overcome these 
intracellular barriers. 
Internalized gene transfer complexes are mostly found in intracellular vesicles such 
as endosomes. Entrapment in endosomes is thought to be associated with 
degradation of the complexes upon endosomal acidification. Therefore, subsequent 
release of particles into the cytoplasm represents a major bottleneck to gene delivery 
(38;39). PEI polyplexes can promote endosomal escape to some degree because of 
the ‘proton sponge’ effect (16). PEI polyplexes and free PEI have considerable 
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buffering capacity, because PEI is only partially protonated at physiological pH (40). 
Upon intracellular delivery of the DNA particle, the natural acidification within the 
endosome triggers protonation of complex-bound and free PEI, inducing chloride ion 
influx, osmotic swelling and destabilization of the vesicle which finally leads to 
release of the polyplexes into the cytoplasm (41). However, this proton sponge effect 
is apparently not sufficient to release the majority of PEI particles from the vesicles. 
In particular, endosomal escape represents a major hurdle to efficient gene transfer 
with small PEI polyplexes at low concentrations (19).  
Since viruses have developed mechanisms to induce efficient endosomal escape, 
inactivated viruses, for example adenovirus, have been combined with PEI 
polyplexes to promote better endosomal release (42). A major drawback in using 
viruses, however, is their immunogenicity as well as their capacity to trigger 
inflammatory responses. To overcome these obstacles, a novel strategy to improve 
intracellular delivery of nonviral vectors was to incorporate membrane active peptides 
into the vector system. Such peptides were derived from viral proteins (25), toxins 
(43;44) or were synthetically designed (43;45); for review see (46). Among these 
membrane active peptides, the bee venom peptide melittin displayed particular 
strong membrane destabilizing activity, and this peptide successfully enhanced gene 
transfer with lipoplexes (47) and PEI polyplexes (48;49).  
After endosomal release DNA complexes or free DNA have to traffic through the 
cytoplasm towards the nucleus, enter the nucleus and expose the DNA to the cell's 
transcription machinery. This process is not clearly elucidated yet. Passive diffusion 
of DNA within the cytoplasm is restricted (50) especially for larger plasmids, and free 
DNA can be degraded by nucleases within the cytoplasm. Therefore, the delivery of 
DNA towards the nucleus is supposed to depend mainly on the transport of intact 
complexes by microtubule or actin filaments (51). Nuclear import of DNA or DNA 
complexes is another big hurdle, which is currently only easily overcome in rapidly 
dividing cells. For example, transfection of non-dividing cells with PEI polyplexes was 
several log units less effective compared to transfection of mitotic cells where the 
nuclear envelope was broken down (52). Either before or after nuclear import 
dissociation of the complex has to occur in order to allow transcription of the DNA. 
Dissociation of the DNA from PEI in the cytosol or within the nucleus could be due to 
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interaction with an excess of anionic macromolecules such as RNA (53) and/or 
exchange reactions with positively charged histone proteins.  
Despite these barriers, some nonviral vectors such as PEI polyplexes have reached 
high transfection efficiencies in vitro and also in vivo. For example, PEI polyplexes 
carrying a DNA vector for TNF-α expression demonstrated encouraging therapeutic 
effects in various tumor models (54). Notably, tail vein administration of such TNF-α 
polyplexes into tumor bearing mice led to tumor-specific TNF-α expression, tumor 
necrosis and remarkable tumor regression. Therefore, PEI polyplexes are promising 
candidates for the development of improved vector systems.  
1.2.5 Key issues for improved PEI polyplexes 
For improved gene delivery with PEI polyplexes two major issues are i) to improve 
the toxicity profile of the applied vectors and ii) to enhance endosomal escape, one of 
the major barriers limiting gene transfer efficiency. 
1.2.5.1 Improving the toxicity profile of PEI polyplexes 
The low efficiency of PEI polyplexes is currently partly compensated by 
administration of high amounts of these nonviral vectors. However, even PEG-
shielded polyplexes are not inert, and polyplex components can mediate toxic side 
effects. In addition, it was observed previously that in standard PEI polyplexes 
generated at charge ratios above N/P 5 up to 80 % of PEI is unbound (55;56) and 
that cellular toxicity of polyplexes directly correlates with increased N/P ratios (57;58). 
Toxic effects of PEI observed at the cellular level range from changes in the gene 
expression pattern of e.g. endothelial cells (57) to the induction of apoptosis, for 
example in spleen lymphocytes (59). These results suggest that toxicity is at least 
partially attributed to free PEI and that purification of polyplexes to remove such 
contaminating polycations would be desirable. A stable formulation of clearly defined 
composition is also indispensable to fulfill general requirements of a potential 
therapeutic gene delivery system. Recently, a method based on ultrafiltration was 
used in order to remove free PEI (55). However, the removal of free PEI using this 
method was incomplete (56). 
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Therefore, the first aim of this thesis was to develop an easy and effective method 
which allows complete removal of free PEI from polyplexes. Based on this method, a 
further aim was to study transfection properties of such purified polyplexes in vitro 
and to evaluate their toxicity profiles in comparison to non-purified polyplexes. 
Moreover, the aim was to clarify the role of free PEI in gene delivery with PEI 
polyplexes at the cellular level.  
1.2.5.2 Enhancing endosomal escape of PEI polyplexes 
As mentioned above, one major barrier limiting the transfection efficiencies of current 
polyplexes is poor endosomal release. The membrane active peptide melittin is one 
example of a pore-forming peptide that has been used to enhance the delivery of 
lipoplexes (47) and polyplexes (48). Melittin is the major toxic component of the 
honey bee venom and consists of 26 amino acids. Its structure can be divided into 
three domains (Fig. 3): an α-helical, hydrophobic domain (residue 1 to 13), an α-
helical amphipathic region (residue 14 to 20) and a non-helical positively charged C-
terminal region (residue 21 to 26).  
Fig. 3 Structure of melittin. Melittin contains a hydrophobic (residue 1 to 13) and an amphipathic 
(residue 14 to 20) α-helical region, which are connected by the helix breaker proline at position 14. 
The cationic C-terminal region (residue 21 to 26) is non-helical. 
Because of its positive charges, melittin has been used as DNA condensing agent 
(47;60). Gene transfer efficiency of melittin/DNA complexes, however, was low and 
concomitant high toxicity was observed most likely because such complexes were 
unstable, and free melittin exposed pronounced cellular toxic effects in the 
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transfected cells. To achieve efficient and stable gene transfer formulations 
endosomal release agents like melittin have to be stably incorporated into the 
complexes. Therefore, melittin was covalently bound to the lipophilic residue dioleoyl-
phosphatidylethanolamine. The hybrid molecule dioleoyl-melittin enabled efficient 
binding to DNA and high levels of reporter gene expression in different mammalian 
cells (47). Melittin was also used in PEI polyplexes. Melittin covalently attached to 
PEI significantly increased reporter gene expression in a broad range of cell lines, 
and even slowly dividing primary cells were susceptible to transfection (48). Another 
melittin-PEI conjugate with low molecular weight PEI was used to successfully 
enhance the delivery of RNA polyplexes (49). In these melittin-PEI conjugates, the 
polycation was covalently bound to the N-terminus of melittin. 
These results indicate that melittin has the capacity to improve endosomal escape of 
nonviral vectors such as PEI polyplexes. The cationic character of melittin is of 
advantage for the use in polycation-based gene delivery systems, since covalent 
attachment of a positive peptide to a polycation will not lead to aggregation effects 
due to charge interactions between the peptide and the polycation. Incorporation of 
melittin into DNA polyplexes can even further stabilize the complex with DNA. In 
addition, synthetic all-(D)-melittin has hemolytic and antibacterial activities 
comparable to the L-enantiomer (61;62) which offers the opportunity to use non-
immunogenic all-(D)-melittin for the generation of non-immunogenic polyplexes. 
Therefore, melittin was of special interest in the current thesis for the development of 
optimized PEI polyplexes with improved endosomal release capacity. 
For the optimal incorporation of melittin into PEI polyplexes, the site of linkage to PEI 
was considered to be important, since it might affect the process of melittin-induced 
membrane pore formation triggering endosome destabilization. According to 
literature, melittin first inserts its N-terminus into the lipid bilayer (Fig. 4). In contrast, 
the cationic C-terminus does not insert but serves as a membrane anchor by 
interaction with the negatively charged lipid headgroups (63-66).  
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Fig. 4 Model of melittin inserted into a lipid bilayer. The cationic C-terminus of melittin (blue) anchors 
the peptide at the negatively charged lipid headgroups. The hydrophobic and amphipathic α-helical 
regions of melittin (purple) are inserted into the lipophilic core of the bilayer. Adapted from Bachar et 
al. (65). 
With an increase in membrane-bound melittin, the peptide induces transmembrane 
pores according to the carpet or toroidal model (Fig. 5) (67). This results in lysis of 
bilayer membranes, e.g. lysis of erythrocytes. Sequence requirements for lytic 
melittin analogs include a free positively charged N-terminus (68;69) and a positively 
charged C-terminus (69;70).  
Fig. 5 Schematics of the toroidal model. The dark layers represent the headgroup regions of bilayers. 
Melittin monomers are represented by the red cylinders with the cationic C-terminal region shown in 
blue. The toroidal pore is formed by the lipid monolayer and melittin peptides which are in contact with 
the lipid headgroups. Adapted from Yang et al. (67). 
Although the exact mechanism of pore formation remains to be elucidated, covalent 
attachment of the polycation PEI to the N-terminus of melittin is expected to prevent 
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membrane insertion and pore formation, whereas conjugation via the C-terminus is 
thought to enhance membrane anchoring and insertion of melittin.  
To determine the optimal site of melittin-linkage to PEI, the strategy applied in this 
thesis was to synthesize two different melittin-PEI conjugates with PEI covalently 
attached to either the C-terminus or the N-terminus of non-immunogenic all-(D)-
melittin. Polyplexes generated with these conjugates should be compared regarding 
their gene transfer efficiency, their membrane destabilizing activity and their capacity 
to induce endosomal release. The conjugate which shows the highest potency of 
membrane destabilization should then be further optimized for lytic activity at pH 5 to 
produce conjugates that are highly active inside acidic vesicles such as endosomes. 
To obtain melittin-PEI conjugates with high lytic activity at pH 5, sequence 
modifications with glutamic acid residues or histidine residues were introduced at the 
C-terminus or the N-terminus of melittin. At physiological pH such melittin analogs do 
not fulfill the charge requirements of active melittin analogs. At acidic pH, however, 
glutamic acid and histidine are fully protonated which should restore all sequence 
requirements resulting in active pore-forming peptides and peptide conjugates.  
Finally, the aim was to incorporate the most active melittin PEI conjugates into 
surface-shielded and receptor-targeted PEI polyplexes. These polyplexes should be 
purified from unbound, potentially toxic PEI or melittin-PEI conjugates. Such a 
polyplex formulation would represent an example for the development of an artificial 
virus-like vector: it carries different functional domains which enable stabilization, 
shielding against unspecific interactions, cell targeting, and efficient intracellular 
delivery.  
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2 Materials and Methods 
2.1 Chemicals and reagents 
Branched PEI (B-PEI) with an average molecular weight of 25 kDa was obtained 
from Sigma-Aldrich (Taufkirchen, Germany). Linear PEI (L-PEI) with an average 
molecular weight of 22 kDa is available from Euromedex (Exgen 500, Euromedex, 
Souffelweyersheim, France). PEI was used at a 1 mg/ml stock solution neutralized 
with HCl. 
Succinimidyl 3-(2-pyridyldithio) propionate (SPDP) was purchased from Fluka 
(Buchs, Switzerland).  
Cysteine-modified melittin peptides and melittin analogs were obtained from 
Genzentrum (group of G.J. Arnold, Munich, Germany), or IRIS Biotech (Marktredwitz, 
Germany). Peptides were synthesized with a purity of > 95 % and were used as 
acetate salts after lyophilization in 4 % acetic acid. 
Melittin with a cysteine residue at the N-terminus of melittin (N-mel) had the following 
sequence: 
N-mel:  CIGA VLKV LTTG LPAL ISWI KRKR QQ 
Glycine-1 of native melittin was replaced by cysteine.  
The sequence of melittin with cysteine at the C-terminus of melittin (C-mel) was: 
C-mel:  GIGA VLKV LTTG LPAL ISWI KRKR QQC  
Cysteine was added to the sequence of native melittin at position 27.  
N-mel was synthesized both in all-(L) and in all-(D)-configuration. C-mel was 
synthesized using (D)-amino acids. 
C-mel-analogs (CMA) with acidic modified sequences were synthesized using (L)-
amino acids and had the following structures: 
CMA-1:     EE  GIGA VLKV LTTG LPAL ISWI KRKR QQC 
CMA-2:   GIGA VLKV LTTG LPAL ISWI HHHH EEC 
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CMA-3:   GIGA VLKV LTTG LPAL ISWI KRKR EEC 
CMA-4:     EE  GIGA VLKV LTTG LPAL ISWI HHHH QQC 
Egg phosphatidylcholine (egg PC) was purchased from Lipoid (Ludwigshafen, 
Germany). Calcein, trinitrobenzenesulfonic acid (TNBS) and all other chemicals were 
purchased from Sigma-Aldrich (Taufkirchen, Germany). 
PEG-PEI22 (molar ratio of 20 kDa PEG to 22 kDa L-PEI was 2/1) and PEG-PEI25 
conjugates (molar ratio of 20 kDa PEG to 25 kDa B-PEI was 1/1) were synthesized 
and purified as previously described in Kursa et al. (71). EGF-PEG-PEI25 conjugate 
linked with a heterobifunctional 3.4 kDa PEG derivative was synthesized as 
described in (28).  
Plasmid pCMVLuc (Photinus pyralis luciferase under control of the CMV 
enhancer/promoter) described in Plank et al. (25) was produced endotoxin-free by 
Elim Biopharmaceuticals (San Francisco, CA, USA) or Aldevron (Fargo, ND, USA). 
Plasmid pEGFP-N1 (encoding Enhanced Green Fluorescent Protein (EGFP) under 
the control of the CMV promoter) was purchased from Clontech Laboratories, Inc. 
(Palo Alto, CA, USA). 
2.2 Quantitative analysis of B-PEI and L-PEI 
2.2.1 TNBS assay 
The concentration of L-PEI and B-PEI was measured by trinitrobenzenesulfonic acid 
(TNBS) assay (72). Standard PEI solutions and test solutions containing B-PEI or L-
PEI were serially diluted in 0.1 M sodium tetraborate to a final volume of 100 µl using 
a 96 well plate, resulting in PEI concentrations of 10 to 40 µg/ml or 100 to 400 µg/ml 
for B-PEI or L-PEI, respectively. To each well 2.5 µl of TNBS (75 nmol) diluted in 
water was added. TNBS reacts with primary amino groups of PEI to form colored 
trinitrophenylated derivatives. After 10 min at room temperature (RT), absorption was 
measured at 405 nm using a microplate plate reader (Spectrafluor Plus, Tecan 
Austria GmbH, Grödig, Austria).  
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2.2.2 Copper complex assay 
L-PEI was also quantified by a copper complex assay at 285 nm following the 
procedure published by Ungaro et al. (73). Equal amounts (100 µl) of Copper-(II)-
sulfate dissolved 0.1 M sodium acetate (0.23 mg/ml), pH 5.4 were mixed with 
standard L-PEI samples or test solutions of L-PEI containing 10 to 60 µg/ml L-PEI 
diluted in water. The resulting Cu(II)/PEI-complexes were quantified by measuring 
the absorbance at 285 nm using a Cary 3 Bio spectrophotometer (Varian, Mulgrave, 
Australia). For the quantification of L-PEI in the presence of DNA, the concentration 
of L-PEI is calculated by the equation: 
C L-PEI = (ABSTOT – ABSDNA) / ε L-PEI/Cu(II) ∗ b 
ABSTOT:  absorbance at 285 nm of L-PEI/Cu(II) in the presence of DNA 
ABSDNA:  absorbance at 285 nm of the L-PEI polyplex 
ε L-PEI/Cu (II):  molar absorptivity of L-PEI/Cu(II) at 285 nm (ε L-PEI/Cu(II) = 6.31 x 105) 
b:   fixed optical path length (cm) 
Since the L-PEI content is measured at 285 nm (as L-PEI/Cu(II) complex), the 
absorption of DNA (ABSDNA) present in the solution is substantial and must be 
subtracted from the total absorption (ABSTOT). 
2.3 Covalent labeling of DNA and PEI 
Plasmid pCMVLuc was covalently labeled with the fluorophore Cy3 using the Label 
IT kit (MIRUS, Madison, WI, USA) according to the manufacturer’s instructions. Cy3 
content was measured by absorption at 552 nm and DNA was quantified by 
measuring the absorbance at 260 nm. On average one Cy3 molecule was bound per 
50 bp. 
PEI was covalently labeled with Cy5 by suspending one vial of FluoroLinkTM Cy5 
monofunctional dye (Amersham Biosciences, Freiburg, Germany) in 1 ml of L- or B-
PEI solution (1 mg/ml PEI) in HEPES-buffered saline (HBS, 150 mM NaCl, 20 mM 
HEPES, pH 7.1). After 2 h at RT unreacted dye was removed by size exclusion 
chromatography using a Sephadex G25 superfine column (Pharmacia Biotech, 
Uppsala, Sweden) equilibrated in HBS. Cy5 content was measured by absorption at 
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663 nm; PEI content was measured by TNBS assay (2.2.1). The molar ratios of 
PEI/Cy5 were 1/2 and 2/1 for L-PEI and B-PEI, respectively. 
2.4 Conjugate synthesis 
2.4.1 Synthesis of 3-(2-pyridyldithio)-propionate-modified B-PEI 
B-PEI (1.25 µmol) in 2 ml buffer (0.35 M NaCl, 20 mM HEPES, pH 8) was mixed with 
3-(2-pyridyldithio)propionic acid N-hydroxy-succinimide ester (SPDP, 25 µmol) 
dissolved in 200 µl dimethyl sulfoxide (DMSO). After 2 h at RT B-PEI with 
pyridyldithio-propionate-linkers (B-PEI-PDP) was purified by gel filtration using an 
Äkta Basic HPLC System (Amersham Biosciences, Freiburg, Germany) equipped 
with a Sephadex G-25 superfine HR 10/30 column (Pharmacia Biotech, Uppsala, 
Sweden) equilibrated in 250 mM NaCl, 20 mM HEPES, pH 7.4; the flow rate was 
0.5 ml/min. The void fractions containing PEI were pooled, aliquots were snap frozen 
in liquid nitrogen and stored at -80°C. PEI content was measured by TNBS assay 
(2.2.1). The degree of modification with dithiopyridine linker was determined 
spectrophotometrically at 343 nm by release of pyridine-2-thion (molar absorptivity = 
8080 M-1 cm-1) after reduction of an aliquot with excess dithiothreitol (DTT, 100 mM). 
For the synthesis of mel-PEI and CMA-PEI conjugates, two different PEI-PDP 
batches were used with a molar ratio of PEI/PDP of approximately 1/15 and 1/10, 
respectively.  
2.4.2 Synthesis of C-mel-PEI and N-mel-PEI conjugates  
The cysteine-modified C-mel or N-mel peptides (2.5 µmol) were dissolved in 500 µl of 
0.5 M NaCl, 20 mM HEPES, pH 7.1 and mixed with 450 µl PEI-PDP (90 nmol PEI, 
1.35 µmol PDP) diluted in the same buffer under argon. The molar excess (1.8-fold) 
of peptide to PDP present in PEI-PDP was used to enhance reaction with the 
dithiopyridine linker. After 4 h at RT released thiopyridone was measured at 343 nm 
to determine the extent of the reaction. Melittin-PEI conjugates were purified on a 
Macroprep High S cation-exchange column (Bio-Scale MT 2, BioRad, Munich, 
Germany) by gradient elution with 10 % to 60 % of buffer A (Buffer A: 5 M NaCl, 
20 mM HEPES, pH 7.1; buffer B: 20 mM HEPES pH 7.1) at a flow rate of 0.5 ml/min. 
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Conjugates were eluted between 2 and 3 M NaCl as monitored at 230 nm and 
280 nm. Main fractions were pooled, concentrated and desalted (final salt 
concentration 75 to 150 mM) on Centricon Plus-20 centrifugal filter units (10 kDa cut 
off, Millipore, Bedford MA, USA). Conjugates were sterile filtered and aliquots were 
snap frozen in liquid nitrogen and stored at -80°C. B-PEI content of the melittin-PEI 
conjugates was determined by TNBS assay (2.2.1). Melittin also reacts with TNBS 
but molar absorptivity of trinitrophenylated melittin derivatives is approximately 10-
fold lower than the colored product with PEI and, therefore, quantification of B-PEI is 
not significantly affected by the presence of melittin. The concentration of melittin in 
the conjugates was measured by absorption at 280 nm (molar absorptivity of melittin 
= 5570 M-1 cm-1). C-mel-PEI and N-mel-PEI conjugates were obtained with a mean 
recovery of 55 % based on analysis of PEI (50 nmol of PEI and 840 nmol of melittin). 
The molar ratio of PEI to melittin was 1/16.  
2.4.3 Synthesis of CMA-PEI conjugates 
PEI conjugates of melittin analogs (CMA-PEI conjugates) were prepared similarly as 
described for C- and N-mel-PEI conjugates (2.4.2). In brief, the dissolved peptides 
were mixed with PEI-PDP (molar ratio of PEI/PDP was 1/10) at a 1.7- (CMA-1), 2.5- 
(CMA-2), 2.2- (CMA-3) and 2.2-fold (CMA-4) molar excess of peptide to PDP. Since 
the melittin analogs CMA-3 and CMA-4 had limited solubility at pH 7, the pH of the 
reaction mixture was adjusted to pH 5 and pH 4 for synthesis of CMA-3-PEI and 
CMA-4-PEI, respectively. Conjugates were purified by cation-exchange 
chromatography as described above and then concentrated using a 10 ml stirred 
ultrafiltration cell (Millipore, Bedford MA, USA) equipped with an ultrafiltration 
membrane of regenerated cellulose (10 kDa cut off, Millipore, Bedford MA, USA). 
Before use, the membrane was conditioned with PEI by filtration of PEI (2 mg) in 
10 ml water to reduce unspecific binding of the conjugates to the membrane. The 
conjugates were then concentrated and desalted to a final salt concentration of 30 to 
60 mM NaCl, 20mM HEPES, pH 7.1. Conjugates were sterile filtered and aliquots 
were snap frozen and stored at -80°C. PEI concentration of the conjugates was 
measured by TNBS assay (2.2.1), and the peptide concentration was calculated 
based on the molar absorptivity of melittin at 280 nm. In the case of incomplete 
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reaction of the peptides with the PDP linkers, the amount of conjugated peptide was 
determined at 343 nm by release of pyridine-2-thion from residual PDP linkers after 
reduction with DTT. Conjugates were obtained with recoveries based on analysis of 
PEI of 40 % (CMA-1-PEI, 80 nmol PEI, 380 nmol CMA-1), 7 % (CMA-2-PEI, 10 nmol 
PEI, 80 nmol CMA-2), 15 % (CMA-3-PEI, 35 nmol PEI, 225 nmol CMA-3) and 11 % 
(CMA-4-PEI, 20 nmol PEI, 150 nmol CMA-4); the molar ratios of PEI to CMA-peptide 
were 1/5-8.  
An improved purification procedure was developed for the synthesis of CMA-2-PEI 
and CMA-3-PEI conjugates. The new protocol is based on size exclusion 
chromatography and leads to higher yields of purified conjugates. Superdex 75 prep 
grade (60 ml) in water (Amersham Biosciences, Freiburg, Germany) was conditioned 
by drop wise application of 10 ml B-PEI (10 mg) to reduce unspecific binding of the 
conjugates. The conditioned gel material was filled into a HR 10/30 column 
(Pharmacia Biotech, Uppsala, Sweden) and equilibrated in 0.5 M NaCl, 20 mM 
sodium acetate, pH 5 at a flow rate of 0.5 ml/min. Conjugates were applied to the 
column and the void fractions containing PEI were dialyzed against 50 mM NaCl 
20 mM HEPES, pH 7.4 using a 5 ml QuixSep dialyzer (Roth, Karlsruhe, Germany) 
equipped with a 14 kDa cut off membrane. After dialysis, conjugates were sterile 
filtered and aliquots were snap frozen in liquid nitrogen and stored at -80°C. CMA-2-
PEI and CMA-3-PEI conjugates were obtained with a recovery of 53 % (CMA-2-PEI, 
100 nmol PEI, 900 nmol CMA-2) and 30 % (CMA-3-PEI, 60 nmol PEI, 540 nmol 
CMA-3) based on analysis of PEI.  
2.5 Polyplex formation 
Plasmid DNA encoding luciferase or EGFP was condensed with PEI or peptide-PEI 
conjugates at an N/P ratio of 6. DNA/PEI polyplexes were prepared at a final DNA 
concentration of 20, 100 or 200 µg/ml as described in (74). Briefly, indicated amounts 
of plasmid DNA and PEI or peptide-PEI conjugates were each diluted in HEPES-
buffered glucose (HBG, 5% (w/w) glucose, 20 mM HEPES, pH 7.1) and rapidly mixed 
by pipetting up and down 5 to 8 times. 
Materials and Methods 25 
EGF-receptor-targeted polyplexes were prepared by first diluting and mixing EGF-
PEG-PEI and PEG-PEI conjugates with free PEI or peptide-PEI conjugates at 
indicated ratios in HBG. The used ratios (% w/w) were all based on the PEI content 
of the different components. The PEI conjugate buffer solution was then mixed with 
plasmid DNA diluted in HBG at an N/P ratio of 6 and a final DNA concentration of 
20 or 100 µg/ml.  
Targeted and non-targeted polyplexes were allowed to stand for at least 20 min at 
RT before use. 
2.6 Measurement of particle size and zeta potential 
Particle size of transfection complexes was measured by laser-light scattering using 
a Malvern Zetasizer 3000HS (Malvern Instruments, Worcestershire, UK). Polyplexes 
were generated in HBG at DNA concentrations of 100 or 200 µg/ml and subsequently 
diluted to 10 µg/ml prior to measurement. Targeted polyplexes were prepared and 
analyzed in HBS at a DNA concentration of 20 µg/ml. For estimation of the surface 
charge, transfection complexes were diluted in 10 mM NaCl to give a final DNA 
concentration of 2 µg/ml and the zeta potential was measured as previously 
described (75). The average conductivity observed for all formulations was 
approximately 1 mS.  
2.7 Purification of polyplexes by size exclusion chromatography 
Size exclusion chromatography (SEC) was performed using a BioLogic HR System 
equipped with a Bio-Scale MT 2 column (7 x 52mm, 2.3 ml column volume; Bio-Rad 
Munich, Germany) packed with Sephacryl S-200 HR (molecular weight exclusion limit 
250 kDa for globular proteins; Pharmacia Biotech, Uppsala, Sweden). After 
equilibration in HBG, the column was conditioned by a single application of 200 µg L- 
or B-PEI to reduce unspecific adsorption of polyplexes. Volumes up to 2 ml 
containing up to 200 µg/ml DNA/PEI polyplexes were loaded onto the column. SEC 
was performed at a flow rate of 0.5 ml/min and fractions of 0.3 ml were collected. The 
elution of DNA polyplexes was monitored at 254 nm. Fractions containing the major 
amounts of DNA were pooled and the DNA was quantified by measuring the 
absorbance at 260 nm. DNA concentration was calculated by 1 OD260 = 45 µg/ml or 
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40 µg/ml for DNA bound to L-PEI or B-PEI, respectively. These values have been 
calculated by comparing standard PEI polyplexes with free plasmid DNA (1 OD260 = 
50 µg/ml). L-PEI content of the fractions was quantified by copper complex assay 
(2.2.2) and B-PEI content was analyzed by TNBS assay (2.2.1). The TNBS assay is 
not significantly affected by the presence of DNA. From the concentrations of PEI 
and DNA determined in the purified polyplexes, their final N/P ratios were calculated. 
N/P ratios of purified complexes were also verified by DNA mobility shift assay using 
agarose gel electrophoresis (76). 
2.8 Cell culture 
Cell culture media, antibiotics and fetal calf serum (FCS) were purchased from 
Invitrogen GmbH (Karlsruhe, Germany). All cultured cells were grown at 37° C in 5 % 
CO2 humidified atmosphere. CT 26 murine colon carcinoma cells (ATCC CRL-2638), 
B16-F10 murine melanoma cells (kindly provided by I.J. Fidler, Texas Medical 
Center, Houston, TX, USA) and HeLa human cervical carcinoma cells (ATCC CCL-2) 
were cultured in DMEM supplemented with 10 % FCS. A-10 rat aortic smooth muscle 
cells (DSZM, ACC 132) were grown in DMEM supplemented with 20 % FCS. 
Neuro2A murine neuroblastoma cells (ATCC CCl-131) and Renca-EGFR mouse 
renal carcinoma cells stably transfected with pLTR-EGFR and pSV2neo (kindly 
provided by Winfried Wels, Georg-Speyer-Haus, Frankfurt am Main, Germany) were 
cultured in RPMI-1640 with Glutamax I medium supplemented with 10 % FCS and 
0.5 mg/ml geneticin (for Renca-EGFR only). HUH-7 hepatocellular carcinoma cells 
(JCRB 0403; Tokyo, Japan) were grown in DMEM high glucose/F12 (1/1) 
supplemented with 10 % FCS. Primary endothelial cells (PEC) were isolated from 
explants of porcine aortic vessels and cultured in M 199 medium supplemented with 
10 % FCS, 4 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 
2.5 mg/ml amphotericine B as described in (77). 
2.9 Luciferase reporter gene expression 
Cells were plated in 96 well plates (TPP, Trasadingen, Switzerland) at a density of 
104 cells (PEC and Neuro2A cells) or 5 x 103 cells (all other cell lines) per well 24 h 
prior to transfection. Transfection complexes with indicated amounts of DNA 
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(pCMVLuc) were added to the cells in 100 µl fresh culture medium containing 
100 U/ml penicillin and 100 µg/ml streptomycin. Culture medium (100 µl) was added 
4 h after transfection. When using targeted polyplexes for transfection, medium was 
replaced after 4 h by 200 µl fresh culture medium. Gene expression was measured 
after 24 h. Detection of luciferase activity was carried out as described recently (48). 
Transfection efficiency was expressed as relative light units (RLU) per seeded cells 
(mean +/- SD of triplicates). Two ng of recombinant luciferase (Promega, Mannheim, 
Germany) correspond to 107 light units.  
2.10 EGFP reporter gene expression 
HeLa cells were seeded in 24 well plates (TPP, Trasadingen, Switzerland) at a 
density of 3 x 104 cells per well 24 h prior to transfection. Transfection complexes with 
indicated amounts of DNA (pEGFP-N1) were added to the cells in 500 µl fresh 
culture medium containing 100 U/ml penicillin and 100 µg/ml streptomycin. Culture 
medium (500 µl) was added 4 h after transfection. Cells were harvested 24 h after 
transfection by treatment with trypsin/EDTA solution (Invitrogen GmbH, Karlsruhe, 
Germany) and kept on ice until analysis. The DNA stain propidium iodide (PI) was 
added to the cell suspension at 1 µg/ml to discriminate between viable and dead 
cells. PI only penetrates the nucleus after cell membrane integrity is lost. The 
percentage of dead cells and transfected cells was quantified using a CyanTM MLE 
flow cytometer (DakoCytomation, Copenhagen, Denmark). PI fluorescence was 
excited by a UV line at 351-364 nm and emission was detected using a 665±20 nm 
bandpass filter. Dead cells were excluded by gating PI-positive cells by forward 
scatter versus PI fluorescence. EGFP fluorescence was excited at 488 nm and 
emission was detected using a 530±40 nm bandpass filter and a 613±20 nm 
bandpass filter to analyze EGFP positive cells by diagonal gating (19). To exclude 
doublets, cells were appropriately gated by forward scatter versus pulse width, and 
2 x 104 gated events per sample were collected. Experiments were performed in 
triplicates. 
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2.11 Metabolic activity of transfected cells 
Cells were plated in white, clear bottom 96 well plates (Nalge Nunc International, 
Naperville, IL, USA) at a density of 5 x 103 cells per well 24 h prior to transfection. 
Transfection of cells was carried out as described above (2.9). Metabolic activity was 
assayed 24 h after transfection using the CellTiter-Glo Luminescent Cell Viability 
Assay (Promega, Mannheim, Germany) according to the manufacturer’s instructions. 
The assay is based on the quantitative measurement of the cellular ATP content. 
Metabolic activity was calculated as percentage of non-transfected control cells 
(corresponding to 100 % metabolic activity). 
2.12 Flow cytometric analysis of cellular polyplex association 
Cells were seeded in 12 well plates (TPP, Trasadingen, Switzerland) at a density of 
105 cells per well 24 h prior to transfection. PEI polyplexes containing Cy3-labeled 
DNA (10 %) and Cy5-labeled PEI (2 % or 10 % for L-PEI or B-PEI, respectively) were 
added to the cells at a concentration of 3 µg/ml DNA per well in 1 ml fresh culture 
medium. Cells were harvested after 4 h incubation at 37° C by treatment with 
trypsin/EDTA solution (Invitrogen GmbH, Karlsruhe, Germany) and kept on ice until 
cell association of polyplexes was assayed using a Cyan MLE flow cytometer 
(DakoCytomation, Copenhagen, Denmark). The fluorophores Cy3 and Cy5 were 
excited at 488 nm and 635 nm, respectively, and emission was detected at 
575±25 nm and 665±20 nm, respectively. Data acquisition was performed in linear 
mode and data were analyzed in logarithmic mode. To discriminate between viable 
and dead cells, cells were appropriately gated by forward versus sideward scatter; to 
exclude doublets cells were gated by forward scatter versus pulse width, and 2 x 104 
gated events per sample were collected. Experiments were performed at least in 
triplicates. 
2.13 Laser scanning microscopy 
Cells were seeded in Lab-Tek 8 Chambered Coverglasses (Nalge Nunc 
International, Naperville, IL, USA) at a density of 2 x 104 cells per chamber 24 h prior 
to transfection. Cells were transfected with Cy3-labeled DNA complexes (4 % Cy3-
DNA) at a concentration of 2 µg/ml DNA per chamber in 200 µl fresh culture medium 
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supplemented with 20 mM HEPES, pH 7.4. For co-localization analysis, free PEI 
containing 75 % Cy5-labeled PEI was added simultaneously or 4 h post-transfection. 
Live cell imaging was performed 8 h after transfection using a confocal laser 
scanning microscope (LSM 510 Meta, Carl Zeiss, Jena, Germany) equipped with an 
argon and two helium/neon lasers delivering light at 488, 543 and 633 nm, 
respectively. Light was collected through a 63 x 1.4 NA oil immersion objective 
(Zeiss). Cy3 fluorescence was excited with the 543 nm line; emission was collected 
using a 560 nm long-pass filter. Excitation of Cy5 fluorescence was achieved by 
using the 633 nm line, with the resulting fluorescent wavelengths observed using a 
650 nm long-pass filter. No signal overspill between the individual fluorescence 
channels was observed. An optical section thickness of 0.6 µm was chosen. 
Transmitted light images (excitation at 488 nm) were collected using differential 
interference contrast (DIC). Digital image recording and image analysis were 
performed with the LSM 5 software, version 3.0 (Zeiss).  
2.14 Transmission light and epifluorescence microscopy 
Cells were seeded in 48 well plates at a density of 3 x 104 cells per well 24 h prior to 
transfection. Cells were transfected with DNA complexes encoding for EGFP at a 
concentration of 2 µg/ml or 4 µg/ml DNA per well in 500 µl fresh culture medium. 
Transmission light microscopy of living cells was performed 2 h after transfection 
using an Axiovert 200 microscope (Carl Zeiss, Jena, Germany) equipped with a Sony 
DSC-S75 digital camera (Sony Corporation, Tokyo, Japan). Light was collected 
through a 32 x 0.25 NA objective (Zeiss), and images were captured using phase 
contrast. 
Live cell imaging of EGFP expressing cells was performed 24 h after transfection 
using an Axiovert 200 fluorescence microscope (Carl Zeiss, Jena, Germany) 
equipped with a Zeiss Axiocam camera. Light was collected through a 10 x 0.25 NA 
or 20 x 0.4 NA objective (Zeiss). EGFP fluorescence was excited using a 470±20 nm 
bandpass filter, and emission was collected using a 540±25 nm bandpass filter. For 
the labeling of dead cells, PI was added to the culture medium at a concentration of 
1 µg/ml, and PI fluorescence was excited using a 560±30 nm bandpass filter; 
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emission was collected through a 615 nm long-pass filter. Digital image recording 
and image analysis were performed with the Axiovision 3.1 software (Zeiss). 
2.15 Video fluorescence microscopy 
Collagen-coated cover slips were fixed with mounting medium to the bottom of a 
Petri dish containing a hole, thereby forming a round cavity with a glass bottom of 
defined optical thickness and a diameter of approximately 1 cm. HeLa cells were 
seeded into this cavity at a density of 5 x 103 cells. After 24 h the cell membrane was 
labeled by incubation of cells with 2.6 nmol of the lipophilic dye 1,1'-dioctadecyl-
3,3,3',3'-tetramethylindodicarbocyanine (DiD) (Molecular Probes, Leiden, The 
Netherlands) diluted in 1 µl of DMSO and 200 µl culture medium for 10 to 60 min at 
37°C. To generate labeled polyplexes, plasmid DNA was first stained with the dimeric 
cyanine nucleic acid stain TOTO-1 (Molecular Probes) by mixing pCMVLuc (0.25 mg) 
diluted in 100 µl water with TOTO-1 (1.26 nmol) dissolved in 1.26 µl of DMSO. This 
results in an approximate ratio of 300 DNA base pairs to one TOTO-1 dye molecule. 
Such labeled DNA was then used to prepare C-mel-PEI polyplexes as described 
above (2.5). Polyplexes were added to the DiD-labeled cells at a DNA concentration 
of 4 µg/ml in 30 µl of fresh culture medium and cells were immediately viewed by 
video fluorescence microscopy using the spinning disk confocal laser scanning 
microscope system UltraView Live Cell Imager (PerkinElmer, Boston, MA, USA). A 
Krypton-Argon ion laser delivered light at 488 and 568 nm to the confocal scanning 
head. Emission was selected by a 500 nm long-pass and a 600±20 nm bandpass 
emission filter. Light was collected through a 100 x 1.4 NA oil immersion objective 
and images were captured by a cooled digital CCD camera (Hamamatsu Photonics 
K.K., Hamamatsu City, Japan) and acquired using the ImagingSuite Acquisition and 
Processing Software (PerkinElmer). Time-lapse confocal images of cells after the 
addition of C-mel-PEI polyplexes were collected at 34 s intervals for 20 min. An 
optical thickness of 1 µm was chosen. DiD fluorescence was excited with the 568 nm 
line, and emission was collected using a 600±20 nm bandpass filter. Excitation of 
TOTO-1 fluorescence was achieved by using the 488 nm line, with the resulting 
fluorescent wavelengths observed using a 500 nm long-pass filter. Images were 
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processed into AVI movies by using the Volocity 3-D/4-D Visualization software 
(Improvision, Lexington, KY, USA).  
2.16 Erythrocyte leakage assay 
Human erythrocytes were isolated from fresh citrate treated blood and washed in 
phosphate-buffered saline (PBS) by four centrifugation cycles, each at 800 g for 
10 min at 4° C. The erythrocyte pellet was diluted 10-fold in 150 mM NaCl. Peptides 
and peptide conjugates were serially diluted in 90 µl buffer (HBS, pH 7.1 or 150 mM 
NaCl, 15mM citric acid, pH 5) using a V-bottom 96 well plate, resulting in peptide 
concentrations of 0.25 – 16 µM. For 100 % lysis, control wells contained buffer with 
1 % Triton-X-100. Erythrocyte suspension (10 µl, containing approximately 109 
erythrocytes) was added to each well and the plates were incubated at 37 °C for 
30 min under constant shaking. After centrifugation at 300 g for 10 min, 50 µl 
supernatant was analyzed for hemoglobin release at 450 nm using a microplate plate 
reader (Spectrafluor Plus, Tecan Austria GmbH, Grödig, Austria). Experiments were 
performed in duplicates. 
2.17 Liposome leakage assay 
Phosphatidylcholine (PC) liposomes loaded with calcein at a self-quenching 
concentration were prepared using the film-method. Egg PC (12.5 µmol) was 
dissolved in chloroform in a round bottom flask. Solvent evaporation resulted in the 
formation of a thin film on the wall of the glass vessel. The lipid film was dried under 
high vacuum and then hydrated with 5 ml solution of 100 mM calcein (dissolved by 
the addition of 375 mM NaOH) and 50 mM NaCl. Hydration and formation of 
liposomes were facilitated by rotating the flask for 4 h at 40°C. The liposomes were 
subsequently extruded through a 200 nm polycarbonate filter using a hand extruder 
(LiposoFast-Basic, Avestin, Ottawa, Canada) heated to 40°C. Non-entrapped 
material was removed from liposomes by gel filtration on a Sephadex G 25 column in 
200 mM NaCl, 20 mM HEPES, pH 7.4. Purified liposomes were diluted 100-fold in 
150 mM NaCl, 30 mM citrate, pH 5. For leakage assays, peptide conjugates were 
serially diluted in 150 mM NaCl, 30 mM citric acid, pH 5, resulting in peptide 
concentrations of 0.125 – 4 µM. Liposome suspension (100 µl) was added to 100 µl 
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of diluted peptide conjugates in black 96 well plates. For 100 % lysis, liposomes were 
added to control wells containing 1 % Triton-X-100 in buffer. After 30 min incubation 
at RT, plates were assayed for calcein fluorescence at 530 nm (excitation at 485 nm) 
on a microplate reader (Spectrafluor Plus, Tecan Austria GmbH, Grödig, Austria). 
Experiments were performed in duplicates. 
2.18 Cell lysis assay 
HeLa cells were plated in 96 well plates (TPP, Trasadingen, Switzerland) at a density 
of 5 x 103 cells per well, 24 h prior to analysis. Culture medium was removed and 
100 µl of melittin-PEI conjugates serially diluted in serum free DMEM with 30 mM 
citrate, pH 5 were added to the cells at peptide concentrations of 0.125 – 16 µM. 
After 30 min incubation at 37°C metabolic activity of viable, non-lysed cells was 
assayed using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, 
Mannheim, Germany) according to the manufacturer’s instructions. Control cells 
incubated with DMEM pH 5 correspond to 100 % metabolic activity. Experiments 
were performed in duplicates. 
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3 Results 
3.1 Purification of PEI polyplexes 
3.1.1 Purification of PEI polyplexes by size exclusion chromatography 
PEI polyplexes were prepared in HEPES-buffered glucose (HBG) resulting in the 
formation of 100-150 nm particles (see also (19;20)). Size exclusion chromatography 
(SEC) on a Sephacryl S-200 matrix pre-conditioned with PEI was used to purify PEI 
polyplexes after polyplex formation. SEC allowed complete removal of free PEI from 
polyplexes (Fig. 6). Column conditioning with PEI reduced unspecific binding of 
polyplexes and improved polyplex recovery. Up to 80 % recovery rates for both 
plasmid DNA and PEI were obtained (mean recovery of 53 % or 63 % for DNA and 
68 % or 72 % for PEI after SEC of L-PEI and B-PEI polyplexes, respectively).  
Fig. 6. Purification of PEI polyplexes by SEC. Typical elution profile of DNA and L-PEI after purification 
of 650µl DNA/L-PEI polyplex N/P 6 in HBG containing 200µg/ml DNA 
The biophysical properties of L-PEI and B-PEI polyplexes before and after SEC were 
analyzed (Table 1). For both PEI polyplexes, size and surface charge were not 
significantly changed after the removal of free PEI by SEC. SEC of polyplexes with 
different N/P ratios ranging from 6 to 12 resulted in purified polyplexes with a similar 
final N/P ratio of approximately 2.5, suggesting that at this N/P ratio all DNA 
phosphate residues are saturated with positively charged PEI nitrogens. 
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Table 1. Biophysical properties of polyplexes before and after SEC purification 
Purification was also tested with polyplexes generated at a low N/P ratio of 3 or in a 
salt containing buffer (75 mM NaCl, 2.5 % glucose). Polyplex recovery, however, was 
as low as 10 % (data not shown). This is most likely attributed to the increased initial 
particle size (> 300 nm and > 1 µm, respectively) and subsequent loss of the material 
on the column. Aggregated polyplexes probably could not pass in between the gel 
beads and therefore got stuck on the column. 
3.1.2 Reporter gene expression and toxicity of purified polyplexes 
Reporter gene expression (luciferase activity) and cellular toxicity were evaluated in 
three different tumor cell lines (CT 26, B16-F10 and HeLa cells) after the application 
of different polyplex preparations (Fig. 7). For transfection experiments, all polyplexes 
were generated at an N/P ratio of 6. Polyplex preparations included non-purified 
polyplexes, SEC-purified polyplexes and purified polyplexes supplemented with free 
PEI equivalent to the amount of free PEI present in non-purified polyplexes (purified 
plus free PEI). 
2.323.0 +/- 7.5103 +/- 25+
1241.7 +/- 7.2116 +/- 26-B-PEI N/P 12
2.821.6 +/- 2.6124 +/- 10+
627.6 +/- 5.6130 +/- 27-B-PEI N/P 6
2.523.8 +/- 3.6140 +/- 31+
620.8 +/- 3.2150 +/- 35-L-PEI N/P 6
N/P ratioZeta potential 
(mV)
Size (nm)SECPolyplex
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Fig. 7. Reporter gene expression and metabolic activity in different tumor cell lines. CT 26 cells were 
transfected with L-PEI (A) and B-PEI polyplexes (B) with increasing concentrations of DNA. (C) B16-
F10 cells (left) and HeLa cells (right) were transfected with L-PEI polyplexes. Luciferase activity is 
displayed in bars (RLU, left y-axis), metabolic activity is displayed as lines in % of untransfected 
control cells (right y-axis). ‘N’: non-purified polyplexes; ‘P’: purified polyplexes; P + free: purified 
polyplexes plus free PEI added. Mean values + SD of triplicates are shown. 
At low DNA concentrations, purified L-PEI polyplexes (Fig. 7A and C) were up to 20-
fold less efficient in transfection compared to polyplexes containing free PEI (with or 
without SEC). At high DNA concentrations [≥ 8 µg/ml (Fig. 7A CT 26, Fig. 7C HeLa) 
and ≥ 4 µg/ml (Fig. 7C, B16-F10)], however, purified L-PEI polyplexes showed 
equivalent or even higher transfection efficiency than polyplexes with free PEI. The 
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enhanced transfection efficiency may be attributed to a low toxicity of purified 
particles, resulting in the survival of more transfected cells in the absence of excess 
PEI. 
In order to evaluate toxicity of purified polyplexes, metabolic activity of cells was 
determined 24 h after transfection by measuring intracellular ATP levels. L-PEI 
polyplexes containing free PEI exerted high toxicity at high DNA doses [≥ 8 µg/ml 
(Fig. 7A CT 26, Fig. 7C HeLa) and ≥ 4 µg/ml (Fig. 7C, B16-F10)]; metabolic activity 
determined 24 h after transfection was reduced to as low as 10 % of the 
untransfected control cells (Fig. 7A). Using purified L-PEI polyplexes, however, 
metabolic activity was maintained at 50 - 90 % compared to control cells (Fig. 7A and 
Fig. 7C). This indicated that at high DNA doses the calculated enhanced transfection 
efficiency of purified polyplexes was mainly due to the lower toxicity of these particles 
in comparison to non-purified complexes. Therefore, to better estimate gene 
expression of surviving cells, luciferase activity was calculated as RLU related to 
metabolic activity (Fig. 8). Notably, at high DNA doses (15 µg/ml) normalized gene 
expression of purified, low toxic polyplexes was still five-fold higher than that of non-
purified polyplexes which displayed pronounced toxicity (viability 10%, Fig. 7A right).  
Fig. 8 Normalized gene expression. Luciferase activity data from Fig. 7A (transfection of CT 26 cells 
with L-PEI polyplexes) were normalized to the metabolic activity. ‘N’: non-purified polyplexes; ‘P’: 
purified polyplexes; P + free: purified polyplexes plus free PEI added. Mean values + SD of triplicates 
are shown. 
In line with the results obtained with L-PEI particles, purified B-PEI polyplexes 
showed reduced transfection efficiency in CT 26 cells in comparison to polyplexes 
containing free PEI (Fig. 7B). Furthermore, Fig. 7B shows that the difference in 
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transfection efficiency is becoming smaller with rising DNA concentrations. Similar 
results were obtained with B16-F10 and HeLa cells (data not shown). At DNA 
concentrations below 15 µg/ml metabolic activity after transfection with all B-PEI 
polyplexes was only slightly reduced compared to untransfected control cells (Fig. 
7B). At the highest DNA dose tested (15 µg/ml DNA) purified B-PEI polyplexes were 
the least toxic resulting in 10 - 20 % higher metabolic activity compared to polyplexes 
with free PEI. 
Fig. 9 Long term reporter gene expression. B16-F10 cells were transfected with B-PEI (left) and L-PEI 
(right) polyplexes. Luciferase activity was analyzed 24 h, 48 h and 72 h after transfection. ‘N’: non-
purified polyplexes; ‘P’: purified polyplexes; P + free: purified polyplexes plus free PEI added. Mean 
values + SD of triplicates are shown. 
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Long term gene expression using low doses of DNA was analyzed 48 h and 72 h 
after transfection of B16-F10 cells with purified polyplexes or polyplexes containing 
free PEI, and gene expression levels were compared to the levels measured after 
24 h (Fig. 9). The applied low DNA doses were overall non-toxic and transfection with 
all polyplexes resulted in stable levels of gene expression over 72 h. Luciferase 
activity after transfection with purified polyplexes was reduced compared to 
polyplexes with free PEI over the whole expression time monitored.  
Fig. 10 Reporter gene expression and metabolic activity after transfection with aggregated polyplexes. 
B16-F10 cells (left) and CT 26 cells (right) were transfected with aggregated L-PEI polyplexes (size 
> 1µm) with increasing concentrations of DNA. Polyplex aggregates were obtained by adding salt to 
polyplexes generated in HBG. Luciferase activity is displayed in bars (RLU, left y-axis), metabolic 
activity is displayed as lines in % of untransfected control cells (right y-axis). ‘N’: non-purified 
polyplexes; ‘P’: purified polyplexes; P + free: purified polyplexes plus free PEI added. Mean values 
+ SD of triplicates are shown. 
Aggregated polyplexes (≥ 1 µm) are known to mediate high gene transfer efficiency 
in vitro (19;20). Therefore, aggregated L-PEI polyplexes were generated by adding 
HEPES-buffered saline (HBS, 150 mM NaCl) to polyplexes prepared in HBG (final 
DNA concentration 20 µg/ml, final buffer concentration 75 mM NaCl). HBS was 
added 30 min prior to transfection to either non-purified or purified L-PEI polyplexes 
with or without free PEI. Particle size of all aggregated L-PEI polyplexes was larger 
than 1 µm. Gene transfer with non-purified aggregated polyplexes was up to 10-fold 
higher than with the respective purified polyplexes. Metabolic activity with aggregated 
polyplexes containing free PEI was 20 – 70 % compared to control cells, whereas the 
metabolic activity was 60 – 70 % with purified polyplexes (Fig. 10). The influence of 
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free PEI on both gene transfer and toxicity was less pronounced with aggregated 
polyplexes than observed with the small polyplexes generated in HBG. 
3.1.3 Enhanced cellular association of purified PEI polyplexes 
Since purified polyplexes displayed lower transfection efficiency at low DNA 
concentrations, it was further investigated whether this was due to altered cellular 
association. This was studied by flow cytometry using Cy3-labeled plasmid and Cy5-
labeled PEI for complex formation (Table 2).  
Table 2. Cellular association of double-labeled L-PEI and B-PEI polyplexes determined by flow 
cytometry. Median channel values +/- SD of at least triplicates are shown. 
For both L-PEI and B-PEI polyplexes, cellular association of DNA (Cy3 signal) was 
increased with purified polyplexes, and DNA association was reduced upon addition 
of free PEI (purified plus free PEI or free Cy5-PEI). The absence of free PEI in 
purified polyplexes led to significantly reduced total PEI association (Cy5 signal) after 
incubation with L-PEI polyplexes, whereas total PEI association was not altered in 
the corresponding experiment with B-PEI polyplexes. For both L-PEI and B-PEI 
polyplexes, the addition of unlabeled PEI to purified polyplexes reduced cellular PEI 
94.24 +/- 3.8716.17 +/- 0.89purified + free PEI
186.76 +/- 10.3516.37 +/- 0.89purified + free PEI-Cy5
217.83 +/- 12.8538.69 +/- 0.76purified
213.26 +/- 14.4519.04 +/- 1.79non-purified
2.48 +/- 0.092.60 +/- 0.05control
Cy5 signal
(PEI)
Cy3 signal 
(DNA)B-PEI-polyplex
29.82 +/- 1.5110.39 +/- 1.46purified + free PEI
56.51 +/- 6.1010.15 +/- 0.72purified + free PEI-Cy5
38.26 +/- 2.9415.22 +/- 1.46purified
79.50 +/- 8.2210.89 +/- 0.47non-purified
2.17 +/- 0.192.26 +/- 0.07control
Cy5 signal
(PEI)
Cy3 signal 
(DNA)L-PEI-polyplex
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association. Control experiments confirmed that fluorescence intensities of Cy5-PEI 
and Cy3-DNA before and after polyplex formation were similar (no fluorescence 
quenching upon DNA compaction), and there was no signal overspill between the 
two fluorescence channels for Cy3 and Cy5 (data not shown). 
Despite enhanced cellular association, gene transfer efficiency of purified polyplexes 
was reduced compared to non-purified complexes. These results implicated that not 
cellular association but reduced internalization and/or intracellular delivery were the 
major obstacles to efficient gene delivery with purified polyplexes. 
3.1.4 Delayed administration of free PEI enhances gene expression 
To determine whether simultaneous application of free PEI with the polyplexes was 
required for the observed transfection effects, a time course experiment was 
performed. L-PEI was added to CT 26 cells at equivalent amounts that had been 
removed by SEC, either simultaneously with purified L-PEI polyplexes or at 1 h or 4 h 
after transfection without replacing the transfection medium. Luciferase expression 
was determined 24 h after transfection (Fig. 11).  
In line with previous transfection experiments (3.1.2), simultaneous addition of free 
PEI restored the transfection efficiency of purified polyplexes to the level of non-
purified polyplexes. Surprisingly, the addition of free PEI to purified polyplexes at 1 h 
or 4 h after transfection increased reporter gene expression up to 100-fold compared 
to non-purified polyplexes; this effect was most pronounced at low DNA doses. 
Similar results were obtained in B16-F10 cells (Fig. 11B) and with B-PEI polyplexes 
in both CT 26 (Fig. 11C) and B16-F10 cells (Fig. 11D). Metabolic activity of all 
transfected cells was > 80 %. 
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Fig. 11. Reporter gene expression in CT 26 and B16-F10 cells with free L-PEI or B-PEI added at 
different time points. CT 26 cells (A) or B16-F10 cells (B) were transfected with the indicated 
concentrations of L-PEI polyplexes (both purified and non-purified) and free L-PEI was added to the 
cells at different time points after transfection without replacing the transfection medium. CT 26 cells 
(C) and B16-F10 cells (D) were transfected with B-PEI polyplexes and free B-PEI was added at 
different time points. ‘N’: non-purified polyplexes; ‘P’: purified polyplexes; P + free: purified polyplexes 
plus free PEI added simultaneously; ‘1 h after’: purified polyplexes plus free PEI added 1 h after 
transfection; ‘4 h after’: purified polyplexes plus free PEI added 4 h after transfection. Luciferase 
activity is presented as mean values + SD of triplicates. Metabolic activity of all transfected cells was 
> 80 %. 
3.1.5 Intracellular co-localization of free PEI and purified polyplexes 
Free Cy5-labeled L-PEI was added to the cells either simultaneously with Cy3-
labeled purified L-PEI polyplexes (Fig. 12A-C) or 4 h post-transfection when 
polyplexes were already completely internalized (Fig. 12D-F). After both 
simultaneous and delayed addition, the majority of free PEI was found to be co-
localized with the internalized polyplexes at 8 h post-transfection. Control 
experiments with non-purified polyplexes revealed no differences in the intracellular 
pattern of Cy3-DNA distribution in comparison to purified polyplexes. Similar results 
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were obtained with B-PEI polyplexes (data not shown). These microscopic 
experiments were performed in cooperation with Katharina von Gersdorff. 
Fig. 12. Cellular localization of polyplexes and free PEI in CT 26 cells. CT 26 cells were transfected 
with DNA-labeled (Cy3) purified L-PEI polyplexes. Free Cy5-PEI was added either simultaneously (A, 
B, C) or 4h post-transfection (D, E, F) without replacing the transfection medium. Confocal laser 
scanning microscopy with living cells was carried out 8 h after transfection. (A, D) Cy3 fluorescence of 
labeled polyplexes (red fluorescence); (B, E) Cy5 fluorescence of labeled free L-PEI (green 
fluorescence); (C, F) overlay of both fluorescence channels (Cy3 and Cy5) with transmitted light (DIC). 
Yellow fluorescence indicates co-localization of Cy3-labeled polyplexes and Cy5-labeled free PEI. 
In summary, purified PEI polyplexes demonstrated low cellular toxicity compared to 
polyplexes with free PEI. The removal of unbound PEI by SEC reduced the 
transfection efficiency of these purified vectors suggesting that free PEI played an 
important role in intracellular delivery of polyplexes. Cellular co-localization of free 
PEI with internalized PEI polyplexes implicated that free PEI most likely enhanced 
the release of polyplexes from endosomal vesicles after internalization. Hence, 
alternative measures to improve the transfection efficiency of purified PEI polyplexes 
are required, such as incorporation of endosomolytic peptides into the particles. To 
this end, the membrane active peptide melittin and melittin analogs were coupled to 
PEI and the resulting polyplexes were analyzed for their activities in gene transfer.  
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3.2 Comparison of C- versus N-terminally linked melittin-PEI 
conjugates 
3.2.1 Synthesis and purification of C-mel-PEI and N-mel-PEI conjugates 
B-PEI was coupled to the C-terminus (C-mel-PEI) or the N-terminus (N-mel-PEI) of 
all-(D)-melittin by the formation of a disulfide bond (Fig. 13). In addition, B-PEI was 
attached to the N-terminus of melittin in all-(L)-configuration. Dithiopyridine groups 
were first introduced into B-PEI by reaction of its primary amino groups with SPDP 
(78). Upon mixing of B-PEI-PDP with cysteine-modified melittin peptides, the 
dithiopyridine groups react with the free sulfhydryl groups of cysteine to the desired 
conjugates.  
Fig. 13 Synthesis of melittin-PEI conjugates. The primary amino groups of PEI react with the 
succinimidyl group of SPDP resulting in PEI modified with dithiopyridine groups. In a second synthesis 
step the free sulfhydryl groups of cysteine at the N-terminus or the C-terminus of melittin react with 
dithiopyridine to the desired melittin-PEI conjugates. 
Purification of the conjugates was performed by cation-exchange chromatography. 
The conjugate reaction mixture was loaded onto the column at a medium salt 
concentration of 0.5 M NaCl to avoid irreversible binding of the polycations to the 
resin, and subsequent salt gradient elution was performed from 0.5 to 3 M NaCl. This 
allowed relatively high melittin-PEI conjugate recovery rates with an approximate 
yield of 50 % based on analysis of PEI.  
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3.2.2 Reporter gene expression of N-mel-PEI polyplexes with melittin in all-(D) 
versus all-(L)-configuration 
In contrast to previously published N-mel-PEI conjugates (48) which were 
synthesized with all-(L)-peptides, in this thesis the optimal site of melittin linkage to 
PEI was investigated using non-immunogenic all-(D)-melittin-PEI conjugates. All-(D)- 
and all-(L)-melittin were shown to have the same hemolytic and antibacterial activities 
(61;62). Nevertheless, it was unclear whether the transfection efficiency of melittin-
PEI polyplexes depended on the peptide’s enantiomeric configuration. Therefore, PEI 
was covalently attached to the N-terminus of all-(L)-melittin or all-(D)-melittin resulting 
in conjugates with 10 molecules melittin conjugated to one molecule PEI. The 
conjugates all-(L)-N-mel-PEI and all-(D)-N-mel-PEI were used to generate 
polyplexes, and transfection efficiency was determined in B16-F10 cells and HeLa 
cells in comparison to melittin-free B-PEI polyplexes. Mel-PEI polyplexes mediated 
10-fold (all-(L)-N-mel-PEI) and 5-fold (all-(D)-N-mel-PEI) higher levels of luciferase 
activity than polyplexes without melittin (B16-F10, Fig. 14A). Moreover, FACS-
analysis showed that 33 % and 26 % of HeLa cells were EGFP positive after 
transfection with all-(L)-N-mel-PEI and all-(D)-N-mel-PEI polyplexes, respectively, 
whereas transfection with melittin-free B-PEI polyplexes resulted in only 0.5 % EGFP 
positive cells (Fig. 14B).  
Fig. 14 Transfection efficiency of N-mel-PEI polyplexes containing all-(L)-melittin or all-(D)-melittin. 
B16-F10 cells (A) and HeLa cells (B) were transfected with B-PEI polyplexes or N-mel-PEI polyplexes 
of all-(L) or all-(D) melittin. Luciferase (A) and EGFP expression (B) was analyzed 24 h after 
transfection. Mean values + SD of triplicates are shown. 
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These data confirm that N-mel-PEI polyplexes mediate significantly higher 
transfection efficiency compared to polyplexes without melittin (48). Notably, gene 
transfer activity of melittin-PEI polyplexes does not depend on the enantiomeric 
configuration of the bound peptide, and thus, non-immunogenic all-(D)-peptides can 
be used for the generation of optimized melittin-PEI polyplexes. 
3.2.3 Reporter gene expression of C-mel-PEI and N-mel-PEI polyplexes 
To determine whether the site of melittin-linkage to PEI influences gene transfer 
activity, B-PEI was conjugated to the C-terminus (C-mel-PEI) or the N-terminus (N-
mel-PEI) of all-(D)-melittin resulting in conjugates with 16 molecules melittin 
conjugated to one molecule PEI. Transfection efficiencies of polyplexes generated 
with C-mel-PEI or N-mel-PEI conjugates were compared to the efficiency of melittin-
free B-PEI polyplexes. Luciferase reporter gene expression was evaluated in two 
different tumor cell lines (HeLa and CT 26 cells) and in slowly dividing primary 
porcine endothelial cells (PEC) (Fig. 15). Polyplexes were generated at N/P ratios 
ranging from 3 to 9. For all polyplexes an N/P ratio of 6 was found to be optimal for 
transfection of tumor cell lines, whereas N/P 7 was best in PEC cells (data not 
shown). These polyplexes were of small size (110 nm – 135 nm) and positively 
charged with a zeta potential in the range of +25 mV to +31 mV. In both tumor cell 
lines and in PEC cells N-mel-PEI polyplexes mediated the highest levels of luciferase 
activity with up to 25-fold (HeLa), 160-fold (CT 26) and 100-fold (PEC) higher 
transfection efficiencies compared to melittin-free B-PEI polyplexes. C-mel-PEI 
polyplexes were up to 5-fold and 25-fold more efficient than B-PEI polyplexes in 
HeLa and CT 26 cells, respectively. In slowly dividing PEC cells, however, 
transfection with C-mel-PEI polyplexes resulted in the lowest transfection levels 
compared to N-mel-PEI or B-PEI polyplexes. 
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Fig. 15 Reporter gene expression (Luciferase activity) after transfection with C-mel-PEI or N-mel-PEI 
polyplexes. HeLa cells (A), CT 26 cells (B) and PEC cells (C) were transfected with B-PEI polyplexes 
or polyplexes of C-mel-PEI or N-mel-PEI with increasing concentrations of DNA. Luciferase activity is 
presented as mean values + SD of triplicates. 
The percentage of transfected cells was analyzed by flow cytometry after transfection 
of HeLa cells with EGFP encoding DNA complexes (Fig. 16). To exclude damaged 
cells or cell debris, cells were appropriately gated by forward versus sideward scatter. 
In addition, PI was added to the analyzed cell suspension and intact but dead cells 
were excluded by gating only PI negative cells. Transfection with C-mel-PEI or N-
mel-PEI polyplexes at 2 µg/ml DNA resulted in a 3-fold higher percentage of EGFP 
positive cells compared to B-PEI polyplexes; 8 % (C-mel-PEI) and 9 % (N-mel-PEI) 
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EGFP positive cells were achieved compared to 2.5 % positive cells when using B-
PEI polyplexes for transfection (Fig. 16). At the higher DNA concentration (4 µg/ml), 
N-mel-PEI polyplexes were clearly the most efficient complexes. The percentage of 
EGFP positive cells with N-mel-PEI polyplexes was 42 %, whereas transfection with 
B-PEI and C-mel-PEI polyplexes only resulted in 11 % and 16 % of EGFP positive 
cells, respectively.  
Fig. 16 Reporter gene expression (EGFP expression) after transfection with C-mel-PEI or N-mel-PEI 
polyplexes. HeLa cells were transfected with the indicated concentrations of B-PEI polyplexes or 
polyplexes of C-mel-PEI or N-mel-PEI. The percentage of EGFP positive cells is presented as mean 
values + SD of triplicates. 
The high transfection efficiency of N-mel-PEI polyplexes compared to B-PEI and C-
mel-PEI polyplexes at 4 µg/ml DNA was confirmed by analyzing the EGFP 
expression 24 h after transfection using epifluorescence microscopy (Fig. 17A-C). 
The number of green fluorescent HeLa cells was clearly highest after transfection 
with N-mel-PEI polyplexes (Fig. 17C).  
The percentage of PI-labeled cells after transfection with polyplexes at a DNA 
concentration of 2 µg/ml was below 5 % as determined by FACS analysis, indicating 
that polyplexes exposed overall low toxicity. A low percentage of dead cells was also 
obtained after transfection with N-mel-PEI and B-PEI polyplexes at a higher DNA 
concentration of 4 µg/ml DNA. C-mel-PEI polyplexes, however, severely damaged 
cells at 4 µg/ml DNA. The percentage of intact cells was clearly reduced, and about 
50 % of the gated intact cells were labeled with PI. The high percentage of dead PI 
positive cells after transfection with C-mel-PEI polyplexes at 4 µg/ml DNA was also 
visualized by epifluorescence microscopy (Fig. 17E). In contrast, the same amount of 
N-mel-PEI or B-PEI polyplexes exposed only moderate toxicity (Fig. 17D, F).  
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Fig. 17 EGFP expressing HeLa cells before and after live-dead stain with propidium iodide (PI). HeLa 
cells were transfected with B-PEI polyplexes (A, D), C-mel-PEI polyplexes (B, E) and N-mel-PEI 
polyplexes (C, F). Epifluorescence microscopy with living cells was carried out 24 h after transfection. 
Representative pictures of EGFP positive cells (green) (A-C) and dead PI-labeled cells (red) (D-F) are 
shown. 
3.2.4 Toxicity of C-mel-PEI and N-mel-PEI polyplexes 
In order to further evaluate the differences in toxicity of melittin-PEI polyplexes, 
relative metabolic activity was determined 24 h after transfection of HeLa cells by 
measuring intracellular ATP levels (Fig. 18).  
Fig. 18 Metabolic activity of HeLa cells 24 h after transfection. HeLa cells were transfected with the 
indicated concentrations of B-PEI polyplexes or polyplexes of C-mel-PEI or N-mel-PEI. Metabolic 
activity in % of untransfected control cells is presented as mean values + SD of triplicates. 
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At DNA concentrations below 4 µg/ml, metabolic activity after transfection with all 
polyplexes was only slightly reduced compared to untransfected control cells. At high 
DNA doses (4 or 8 µg/ml DNA), however, C-mel-PEI polyplexes dramatically reduced 
metabolic activity to as low as 2 % compared to control cells, whereas with both B-
PEI and N-mel-PEI polyplexes metabolic activity was maintained above 75 %.  
Fig. 19 Cellular disruption of HeLa cells by free or complexed C-mel-PEI. HeLa cells were incubated 
with B-PEI polyplexes (B), N-mel-PEI polyplexes (C), C-mel-PEI polyplexes (D) or C-mel-PEI 
conjugate (E). Transmission light images of living cells were captured after 2 h incubation. (A) 
untransfected control cells. Arrows indicate disrupted HeLa cells and arrow heads vesicles resembling 
membrane blebbing. 
The toxic effects of C-mel-PEI polyplexes were already observed 2 h after 
transfection by light field microscopy (Fig. 19). HeLa cells transfected with C-mel-PEI 
polyplexes at a high DNA dose of 4 µg/ml DNA were severely damaged. Cells 
seemed to be disrupted and vesicles resembling membrane blebbing were observed 
A
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at the cell surfaces (Fig. 19D). Disrupted cells were also observed 2 h after the 
addition of free C-mel-PEI conjugate at concentrations equivalent to the amount of 
complexed C-mel-PEI at 4 µg/ml DNA (Fig. 19E). In contrast, cell morphology after 
transfection with B-PEI polyplexes or N-mel-PEI polyplexes at 4 µg/ml DNA (Fig. 
19B, C) remained similar to untransfected control cells (Fig. 19A). 
3.2.5 Cell lysis induced by C-mel-PEI polyplexes 
The process of HeLa cell disruption after transfection with C-mel-PEI polyplexes at a 
concentration of 4 µg/ml DNA was further investigated using time-lapse confocal 
laser scanning microscopy. Lipid membrane structures of HeLa cells including the 
plasma membrane were labeled with DiD, a fluorescent lipophilic dye that 
spontaneously accumulated within cell membranes. The DNA intercalating dye 
TOTO-1 was used to label DNA complexes of C-mel-PEI. Immediately after start of 
transfection confocal images of cells and C-mel-PEI polyplexes were captured at 
34 s intervals for 20 min. Fig. 20 shows selected confocal images taken from a time-
lapse series.  
Association of C-mel-PEI polyplexes with the plasma membrane and pseudopodia of 
cells was observed within the first minutes after transfection (Fig. 20A), followed by 
contraction of the pseudopodia towards the cell’s body (Fig. 20A-C). Shortly after 
polyplex association blebbing of DiD-stained lipid vesicles from the plasma 
membrane was monitored (Fig. 20C-F). Some labeled C-mel-PEI polyplexes were 
found to be associated with these vesicles, suggesting that the polyplexes induced 
such membrane blebbing. The vesicle formation indicated lysis of the plasma 
membrane which was induced shortly after addition of C-mel-PEI polyplexes. The 
observed cell lysis is most likely related to the membrane destabilizing activity of 
melittin within the conjugate. Similar cell lysis, however, was not detected with free or 
complexed N-mel-PEI conjugate, indicating that the covalent attachment of PEI to the 
C-terminus or the N-terminus of melittin determined the membrane destabilizing 
activity of the resulting melittin-PEI conjugate.  
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Fig. 20 Cell lysis induced by C-mel-PEI polyplexes. DiD-labeled HeLa cells were transfected with 
TOTO-1-labeled C-mel-PEI polyplexes. Confocal laser scanning microscopy with living cells was 
carried out immediately after start of transfection. Selected images of HeLa cells (green fluorescence) 
and polyplexes (red fluorescence) taken from a time-lapse series over 20 min are shown. Arrow heads 
indicate pseudopodia with associated polyplexes and arrows indicate membrane blebbing. 
3.2.6 Lytic activities of C-mel-PEI and N-mel-PEI at neutral pH 
In order to compare the membrane destabilizing activity of C-mel-PEI and N-mel-PEI 
at neutral pH, the lytic activities were tested on erythrocytes (Fig. 21). Erythrocytes 
were incubated with the free melittin peptides (C-mel and N-mel) and melittin-PEI 
conjugates in HBS, pH 7.1, for 30 min at 37°C. The free peptides C-mel and N-mel 
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exposed similar lytic activity over the whole concentration range tested, and 50 % 
lysis was observed at 16 µM and 8 µM melittin with C-mel and N-mel, respectively. 
The lytic activity of N-mel-PEI conjugate was similar compared to the free peptides, 
suggesting that the covalent attachment of PEI to the N-terminus of melittin does not 
significantly affect the lytic activity of the peptide. With N-mel-PEI, erythrocyte lysis of 
50 % was obtained at a concentration of 6 µM melittin. In contrast to N-mel-PEI, the 
lytic activity of C-mel-PEI was significantly higher compared to the free peptides over 
the whole concentration range tested. Hemoglobin release of 50 % was observed at 
a concentration of 2 µM melittin. B-PEI alone did not lead to any detectable 
erythrocyte leakage up to a concentration that was 20-fold higher than the amount of 
PEI in the lysis assays with melittin-PEI conjugates (0.5 mg/ml PEI). These data 
demonstrate that the covalent attachment of PEI to the C-terminus of melittin strongly 
increases the membrane lytic activity of melittin at pH 7.  
Fig. 21 Erythrocyte lysis induced by free melittin and melittin-PEI conjugates at pH 7. Washed human 
erythrocytes were incubated with the free melittin peptides C-mel and N-mel or the conjugates C-mel-
PEI and N-mel-PEI with increasing peptide concentrations. The percentage of lysed erythrocytes is 
presented as mean values +/- SD of duplicates. 
In summary, the toxicity of C-mel-PEI conjugates and the corresponding polyplexes 
seems to be related to the high membrane destabilizing activity of C-mel-PEI which 
leads to strong cell membrane destabilization resulting in membrane blebbing, cell 
lysis and cell death.  
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3.2.7 Endosomolytic activity of C-mel-PEI and N-mel-PEI 
The high toxicity of C-mel-PEI polyplexes may partly explain the reduced transfection 
efficiency of C-mel-PEI polyplexes compared to N-mel-PEI polyplexes. However, C-
mel-PEI polyplexes were still less efficient than N-mel-PEI polyplexes when using 
DNA doses below 4 µg/ml, where both polyplexes exposed low toxicity (Fig. 15, Fig. 
18). This indicated that toxicity could not be the only explanation for the lower 
transfection efficiency of C-mel-PEI. 
Melittin-PEI conjugates were incorporated into the complexes with the intention to 
enhance endosomal release, which is believed to be a major bottleneck to efficient 
gene transfer with nonviral gene delivery systems. The conjugates are supposed to 
induce endosomal escape by destabilization of the endosomal membrane. Since 
endosomes are acidic vesicles (the pH is usually around pH 5 to pH 6), membrane 
lysis assays have been established at pH 5 to obtain a better measure of the 
destabilizing activities of conjugates inside the endosome. For this purpose, 
erythrocytes or calcein loaded PC-liposomes were incubated with melittin peptides or 
melittin-PEI conjugates in buffer of pH 5, and membrane lysis was detected by 
hemoglobin release or calcein release, respectively (Fig. 22A and B). Both assays 
were not affected by the presence of B-PEI. In addition, HeLa cells were incubated 
with peptides or melittin-PEI conjugates in serum free culture medium at pH 5 for 
30 min, and the amount of viable, non-lysed cells was estimated by measuring the 
metabolic activity using the ATP assay (Promega) (Fig. 22C). Incubation of control 
cells at pH 5 for 30 min did not significantly affect their metabolic activity. The 
presence of B-PEI at a concentration of 100 µg/ml slightly reduced metabolic activity 
of cells to approximately 80 % compared to control cells. The influence of PEI in this 
assay was eliminated by the fact that both conjugates carried the same PEI to 
melittin ratio, and cells were exposed to similar amounts of PEI and melittin using 
either C-mel-PEI or N-mel-PEI. Hence, differences in the resulting metabolic activity 
of cells should only be related to the different site of melittin-linkage to PEI. 
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Fig. 22 Membrane lytic activities of melittin peptides and conjugates at endosomal pH 5. Human 
erythrocytes (A), calcein loaded PC-liposomes (B) and HeLa cells (C) were incubated with increasing 
concentrations of the free peptides C-mel and N-mel or the conjugates C-mel-PEI and N-mel-PEI at 
pH 5. The membrane lytic activities were determined by hemoglobin release (A), calcein release (B) 
and analysis of the metabolic activity of residual non-lysed HeLa cells (C). Mean values +/- SD of 
duplicates are shown.  
The free peptides C-mel and N-mel displayed similar lytic activity on liposomes and 
HeLa cells at pH 5, but C-mel was less lytic than N-mel on erythrocytes. The lytic 
activity of N-mel-PEI was similar compared to the activities of the free peptides on 
erythrocytes, liposomes and HeLa cells. In contrast, C-mel-PEI displayed lower lytic 
activity at pH 5 than N-mel-PEI over the whole concentration range and in all three 
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systems tested. Apart from high toxicity of C-mel-PEI polyplexes, the reduced lytic 
activity of C-mel-PEI at endosomal pH 5 may explain the reduced transfection 
efficiency of C-mel-PEI polyplexes. 
In summary, the site of melittin-linkage to PEI has a high impact on the membrane 
destabilizing activity of the peptide. Binding of PEI to the C-terminus strongly 
enhanced the lytic activity at pH 7, whereas binding to the N-terminus retained lytic 
activity at endosomal pH 5. As a consequence, C-mel-PEI polyplexes exposed 
pronounced toxicity because of lysis of the plasma membrane of transfected cells, 
and N-mel-PEI polyplexes were more efficient in transfection because of improved 
endosomal release of internalized polyplexes.  
The high potency of C-mel-PEI to destabilize membranes at neutral pH might be due 
to a reported destabilization mechanism proceeding through membrane insertion of 
the peptide (65). In contrast, N-mel-PEI is supposed to induce lysis by insertion-
independent pore formation (see discussion) (67). Since membrane destabilization 
by membrane insertion requires lower peptide to lipid ratios than destabilization by 
pore formation, C-mel-PEI was considered as the more potent template to generate 
improved endosomolytic conjugates.  
3.3 Improved endosomolytic melittin-PEI conjugates  
The new melittin-PEI conjugates should display improved destabilizing activity at low 
peptide to lipid ratios like C-mel-PEI, but most importantly, they should expose this 
high lytic activity at pH 5 to promote efficient endosome lysis. 
3.3.1 Synthesis and purification of PEI conjugates with melittin analogs 
In order to generate melittin-PEI conjugates with enhanced lytic activity at endosomal 
pH 5, different melittin analogs were designed as shown in Table 3. Sequence 
modifications included the addition of two glutamic acid residues to the N-terminus 
(CMA-1, CMA-4) or to the C-terminus of melittin (CMA-2, CMA-3); in the latter case 
these amino acids replaced neutral glutamine (Gln-25 and Gln-26) residues. At 
physiological pH the carboxyl group of the glutamic acid residues is deprotonated 
and negatively charged, whereas at pH 5 glutamic acid is protonated. In two peptide 
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analogs the basic region KRKR was replaced by histidine residues (CMA-2, CMA-4) 
which are uncharged at physiological pH but positively charged at endosomal pH 5. 
Table 3 Melittin analogs with acidic modified sequences and a C-terminal cysteine residue (CMA). 
Additional or replaced amino acid residues are underlined. 
Since transfection efficiency of melittin-PEI conjugates does not depend on the 
peptide’s enantiomeric configuration (see 3.2.2), and immunogenicity of natural (L)-
amino acids was currently not important for the development of an improved in vitro 
transfection system, melittin analogs were synthesized in all-(L)-configuration 
containing a carboxyl terminal cysteine residue for conjugation to PEI. Conjugate 
synthesis was performed as described above (3.2.1). Purification of the conjugates 
by cation-exchange chromatography resulted in low conjugate recovery except for 
CMA-1-PEI; the yield was 41 % (CMA-1-PEI), 7 % (CMA-2-PEI), 15 % (CMA-3-PEI) 
and 11 % (CMA-4-PEI) based on analysis of PEI. Therefore, a new purification 
protocol was developed using size exclusion chromatography. This method led to 
higher yields of purified conjugates based on analysis of PEI (53 % for CMA-2-PEI 
and 30 % for CMA-3-PEI). All modified melittin-PEI conjugates were shown to consist 
of approximately 5 to 8 molecules of melittin conjugated to one molecule of PEI. 
3.3.2 Endosomolytic activities of CMA-PEI conjugates 
In order to analyze the endosomal release capacities of the modified melittin-PEI 
conjugates compared to C-mel-PEI, the membrane lytic activities of the conjugates 
were tested on erythrocytes at pH 5 similar as described above (3.2.7) (Fig. 23A). In 
addition, HeLa cells were incubated with the conjugates at pH 5, and metabolic 
EE GIGA VLKV LTTG LPAL ISWI HHHH QQCCMA-4
GIGA VLKV LTTG LPAL ISWI KRKR EECCMA-3
GIGA VLKV LTTG LPAL ISWI HHHH EECCMA-2
EE GIGA VLKV LTTG LPAL ISWI KRKR QQCCMA-1
GIGA VLKV LTTG LPAL ISWI KRKR QQCC-melittin
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activity was determined as described above (3.2.7) to estimate the amount of viable, 
non-lysed cells (Fig. 23B).  
Fig. 23 Membrane destabilizing activities of CMA-PEI conjugates at endosomal pH 5. Human 
erythrocytes (A) and HeLa cells (B) were incubated with melittin-PEI conjugates at pH 5 and lytic 
activities were determined by hemoglobin release (A) and analysis of the metabolic activity of non-
lysed HeLa cells (B). Mean values +/- SD of duplicates are shown. 
CMA-4-PEI did not significantly lyse erythrocytes at pH 5 up to a concentration of 
16 µM melittin. CMA-1-PEI displayed similar lytic activity as C-mel-PEI, but both 
conjugates induced less than 50 % lysis within the concentration range tested. 
Strong erythrocyte lysis was only observed with CMA-2-PEI and CMA-3-PEI 
conjugates which induced 50 % hemoglobin release at a concentration of 13 µM 
melittin.  
Consistently, the metabolic activity of HeLa cells was reduced to 50 % after 30 min 
incubation at pH 5 with CMA-2-PEI and CMA-3-PEI at a concentration of 1 µM 
melittin. All other conjugates were less lytic and metabolic activity was reduced to 
50 % at 2 µM melittin (CMA-1-PEI), 3 µM (CMA-4-PEI) and 7 µM (C-mel-PEI). Similar 
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to the results obtained with erythrocytes, CMA-2-PEI and CMA-3-PEI exhibited the 
strongest destabilizing effect at pH 5 on the cell membrane of HeLa cells compared 
to all other conjugates, resulting in the most pronounced reduction of cellular 
metabolic activity.  
3.3.3 Lytic activities of CMA-PEI conjugates at neutral pH 
Ideally, the CMA-PEI conjugates were designed to display high membrane 
destabilizing activity at endosomal pH 5 and low lytic activity at neutral pH to mediate 
low toxicity. Therefore, the erythrocyte leakage activities of conjugates were tested at 
pH 7.1 (Fig. 24). The conjugate CMA-4-PEI did not significantly lyse erythrocytes 
over the whole concentration range tested up to a concentration of 16 µM melittin. C-
mel-PEI and CMA-1-PEI displayed similar lytic activity, with 50 % lysis observed at a 
concentration of 2 µM and 4 µM melittin, respectively. CMA-2-PEI and CMA-3-PEI 
were the most lytic conjugates that induced 50 % hemoglobin release at a 
concentration of 1 µM melittin.  
Fig. 24 Erythrocyte lysis induced by CMA-PEI conjugates at neutral pH. Human erythrocytes were 
incubated with melittin-PEI conjugates with increasing peptide concentrations at pH 7. The percentage 
of lysed erythrocytes is presented as mean values +/- SD of duplicates. 
Overall, two PEI conjugates with melittin analogs, CMA-2-PEI and CMA-3-PEI, 
displayed the desired high membrane lytic activity at endosomal pH 5. These two 
conjugates were therefore the most promising candidates for transfection 
experiments. However, CMA-2-PEI and CMA-3-PEI polyplexes were expected to 
mediate toxic side effects, since these conjugates were also highly lytic at pH 7.  
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3.3.4 Improved endosomolytic melittin-PEI conjugates enhance reporter gene 
expression 
Transfection efficiencies of CMA-PEI polyplexes were compared to the efficiencies of 
C-mel-PEI polyplexes and PEI polyplexes without melittin. Luciferase reporter gene 
expression was evaluated in three different tumor cell lines (CT 26, HeLa and 
Neuro2A cells) and in rat smooth muscle cells (A-10 cells) (Fig. 25). Transfection 
complexes were generated at N/P ratios ranging from 3 to 9. For all polyplexes 
optimal transfection efficiency was found at an N/P ratio of 6 (data not shown). 
Fig. 25 Reporter gene expression after transfection with CMA-PEI conjugates. CT 26 (A), HeLa (B), 
Neuro2A (C) and A-10 cells (D) were transfected with indicated concentrations of PEI, C-mel-PEI and 
CMA-PEI polyplexes. Luciferase activity is presented as mean values + SD of triplicates.  
C-mel-PEI polyplexes were 25-fold (CT 26) and 2-fold (A-10) more efficient than PEI 
polyplexes without melittin. In HeLa cells and Neuro2A cells C-mel-PEI polyplexes 
and PEI polyplexes exposed similar transfection activity. Polyplexes generated with 
the conjugates CMA-1-PEI and CMA-4-PEI were similar or less efficient than C-mel-
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PEI polyplexes. In contrast, CMA-2-PEI and CMA-3-PEI polyplexes mediated 
significantly higher transfection activity than C-mel-PEI polyplexes, with 5-fold 
(CT 26), 10-fold (HeLa), 5-fold (Neuro2A) and 6- to 10-fold (A-10) higher transfection 
efficiencies compared to C-mel-PEI polyplexes. 
In summary, the conjugates CMA-2-PEI and CMA-3-PEI, which exhibited the highest 
membrane destabilizing activity at endosomal pH 5, were also found to be most 
efficient in gene transfer compared to the other melittin-PEI conjugates. 
3.3.5 Toxicity of CMA-PEI polyplexes 
In order to evaluate cellular toxicity of CMA-PEI polyplexes, metabolic activity was 
analyzed 24 h after transfection by measuring intracellular ATP levels (Fig. 26).  
Fig. 26 Metabolic activity after transfection with CMA-PEI polyplexes. HeLa cells were transfected with 
increasing concentrations of PEI, C-mel-PEI and CMA-PEI polyplexes. Metabolic activity in % of 
untransfected control cells is presented as mean values + SD of triplicates. 
At the highest DNA dose that was used to determine luciferase expression (2 µg/ml) 
metabolic activity with all polyplexes was maintained above 75 %. Pronounced 
toxicity was observed when using elevated DNA concentrations of 4 µg/ml or 8 µg/ml. 
At these DNA doses C-mel-PEI strongly reduced metabolic activity to as low as 2 % 
compared to untransfected control cells, while CMA-2-PEI and CMA-3-PEI 
polyplexes reduced metabolic activity to 35 % and 10 %, respectively. Transfection 
with PEI, CMA-1-PEI and CMA-4-PEI polyplexes also reduced metabolic activity of 
cells at high DNA concentrations, but these polyplexes were overall less toxic and 
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metabolic activity was maintained above 50 % compared to untransfected control 
cells. 
Taken together, these data implicate that melittin-PEI conjugates with improved 
endosomolytic activity can be designed by sequence modification of melittin with 
acidic residues. The conjugates CMA-2-PEI and CMA-3-PEI exposed the highest 
lytic activity at endosomal pH 5, and these conjugates were the most efficient in 
transfection suggesting that gene transfer efficiency indeed correlated with lytic 
activity at pH 5. However, CMA-2-PEI and CMA-3-PEI also appeared to be 
significantly toxic which was most likely due to their high membrane destabilizing 
activity at pH 7. Despite these toxic side effects, CMA-2-PEI and CMA-3-PEI were 
promising candidates for the development of improved artificial viruses. 
3.4 Towards artificial viruses 
The membrane active peptide melittin has been shown to improve gene delivery of 
PEI polyplexes. For systemic applicability, however, the positive surface charge of 
polyplexes has to be shielded to avoid unspecific interactions with blood components 
and non-target cells, and targeting ligands have to be included to direct particles 
towards the desired tissue. Nonviral vector systems carrying multiple functional 
domains e.g. for shielding, targeting and improved intracellular delivery represent the 
next generation of nonviral vectors and have been termed ‘artificial viruses’ (18). 
3.4.1 Shielding and targeting of melittin-PEI polyplexes 
For the development of artificial viruses based on B-PEI polyplexes, shielding and 
targeting conjugates had to be incorporated into the particles. Therefore, two PEG-
PEI conjugates were synthesized with PEG of 20 kDa covalently attached to either 
linear PEI of 22 kDa or branched PEI of 25 kDa, resulting in the two conjugates PEG-
PEI22 and PEG-PEI25 as described in (71). The molar ratio of PEG/PEI was 2/1 for 
PEG-PEI22 and 1/1 for PEG-PEI25. For the targeting of polyplexes towards the 
epidermal growth factor (EGF) receptor, which is overexpressed on various tumor 
cells (e.g. HUH-7 human hepatoma cells) (79), the ligand EGF was linked to B-PEI 
by a heterobifunctional 3.4 kDa PEG derivative (EGF-PEG-PEI25) as described in 
(28). The resulting molar ratio of EGF/PEG/PEI within the conjugate was 
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approximately 1/1/1. For the shielding of B-PEI polyplexes, PEG-PEI22 or PEG-
PEI25 conjugates were mixed with free B-PEI at various ratios in HBS. The ratios 
(% w/w) are based on the amount of PEI present in the PEG conjugates or the PEI 
stock solutions. The PEI conjugate mixture was then mixed with DNA diluted in HBS 
at an N/P ratio of 6 and a final DNA concentration of 20 µg/ml. Particles were 
analyzed by laser-light scattering (Table 4). 
Table 4 Size and zeta potential of surface shielded B-PEI polyplexes. DNA complexes with different 
ratios of PEG-PEI22 or PEG-PEI25 shielding conjugate were prepared in HBS at an N/P ratio of 6 and 
a final DNA concentration of 20 µg/ml. Particles were allowed to stand for 30 min before analysis. 
The preparation of unshielded B-PEI polyplexes in HBS resulted in large aggregated 
particles (2,500 nm) due to the salt concentration in the HBS buffer (19). B-PEI 
polyplexes generated in HBS with 10 to 20 % PEG-PEI22 shielding conjugate were 
small (200 to 240 nm) indicating partial shielding. However, zeta potential of these 
particles was positive (+13 to +20 mV), similar to the zeta potential of unshielded 
polyplexes (+17mV). Apparently, the shielding conjugate PEG-PEI22, which has 
been successfully used for shielding L-PEI polyplexes in a previous study (71), is not 
useful to shield B-PEI polyplexes. In contrast, effective shielding of B-PEI polyplexes 
was achieved using 10 to 20 % PEG-PEI25 shielding conjugate resulting in particles 
< 100 nm with near neutral zeta potential (Table 4).  
2.8 +/- 0.894 +/- 2180/20
2.7 +/- 0.874 +/- 1285/15B-PEI/PEG-PEI25
3.4 +/- 1.280 +/- 1690/10
13 +/- 6203 +/- 880/20
20 +/- 5204 +/- 885/15B-PEI/PEG-PEI22
15 +/- 7232 +/- 1090/10
17 +/- 0.82,500 +/- 300200 +/- 23100B-PEI
Zeta potential
(mV)Size (nm)Ratio (% w/w)Polyplex
Results 63 
The incorporation of EGF-PEG-PEI25 targeting conjugate into the polyplexes at a 
ratio (w/w based on PEI) of PEI/PEG-PEI25/EGF-PEG-PEI25 of 80/10/10 % also 
resulted in small and shielded particles (Table 5). When replacing B-PEI by different 
melittin-PEI conjugates, particle size and zeta potential of such shielded and targeted 
polyplexes was not changed (Table 5). 
Table 5 Particle size and zeta potential of shielded and receptor-targeted B-PEI polyplexes. DNA 
complexes were prepared in HBS at an N/P ratio of 6 and a final DNA concentration of 20 µg/ml. 
Particles were allowed to stand for 30 min before analysis. 
3.4.2 Reporter gene expression of shielded and EGFR-targeted melittin-PEI 
polyplexes 
According to transfection experiments with non-shielded, positively charged melittin-
PEI polyplexes, the most efficient polyplexes were generated with the N-terminal 
melittin-PEI conjugate (N-mel-PEI) or conjugates of melittin analogs with PEI linked 
to the peptide’s C-terminus (CMA-2-PEI and CMA-3-PEI). Therefore, these melittin 
conjugates were used to prepare shielded EGFR-targeted polyplexes, and 
transfection efficiency was compared to shielded and targeted polyplexes generated 
with C-mel-PEI conjugate or B-PEI without melittin. For transfection experiments, all 
polyplexes were generated at an N/P ratio of 6 with 10 % PEG-PEI25 and 10 % 
EGF-PEG-PEI25. Luciferase reporter gene expression was evaluated in two EGF-
receptor rich tumor cell lines, HUH-7 and Renca-EGFR cells (Fig. 27). 
2.9 +/- 0.891 +/- 1580/10/10CMA-3-PEI/PEG-PEI25/EGF-PEG-PEI25
4.5 +/- 3155 +/- 1580/10/10CMA-2-PEI/PEG-PEI25/EGF-PEG-PEI25
3 +/- 0.878 +/- 980/10/10N-mel-PEI/PEG-PEI25/EGF-PEG-PEI25
2.5 +/- 0.888 +/- 880/10/10B-PEI/PEG-PEI25/EGF-PEG-PEI25
Zeta potential
(mV)Size (nm)
Ratio 
(% w/w)Polyplex
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Fig. 27 Reporter gene expression after transfection with PEG-shielded and EGF-receptor-targeted 
polyplexes. HUH-7 (A) and Renca-EGFR cells (B) were transfected with indicated concentrations of 
different melittin-PEI polyplexes or PEI polyplexes without melittin. All polyplexes contained 10 % 
PEG-PEI25 for surface shielding and 10 % EGF-PEG-PEI25 for receptor targeting. Luciferase activity 
is presented as mean values + SD of triplicates. 
The incorporation of C-mel-PEI into shielded and EGFR-targeted polyplexes did not 
enhance the efficiency compared to polyplexes without melittin. In contrast, shielded 
EGFR-targeted polyplexes generated with the most effective conjugates N-mel-PEI, 
CMA-2-PEI and CMA-3-PEI mediated significantly enhanced transfection activity 
compared to polyplexes without melittin. The highest levels of reporter gene 
expression were obtained using shielded and targeted CMA-3-PEI polyplexes, which 
showed 8-fold (HUH-7) and 70-fold (Renca) higher transfection efficiency than 
shielded and targeted B-PEI polyplexes without melittin. 
3.4.3 Reporter gene expression and toxicity of purified, shielded and EGFR-
targeted melittin-PEI polyplexes 
The key question was finally whether such optimized shielded and targeted melittin-
PEI polyplexes would retain high transfection efficiency after the removal of free 
melittin-PEI by SEC and whether these polyplexes expose reduced toxicity. Shielded 
EGFR-targeted polyplexes were prepared with PEI or with the melittin-PEI conjugate 
CMA-3-PEI, and these polyplexes were purified to remove unbound PEI or CMA-3-
PEI as described in 3.1.1. Particle size and surface charge were not significantly 
changed after purification, and purified polyplexes remained stable over a period of 
7 days at 4°C with a size of < 150 nm and a near neutral zeta potential. Transfection 
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efficiencies of freshly prepared non-purified and purified polyplexes were evaluated in 
HUH-7 and Renca-EGFR cells (Fig. 28). 
Fig. 28 Reporter gene expression after transfection with purified shielded and targeted polyplexes. 
HUH-7 (A) and Renca-EGFR cells (B) were transfected with indicated concentrations of PEI or CMA-
3-PEI polyplexes which were shielded with PEG-PEI25 and targeted with EGF-PEG-PEI25. ‘N’: non-
purified polyplexes; ‘P’: purified polyplexes. Luciferase activity is presented as mean values + SD of 
triplicates. 
In line with the results obtained with purified, positively charged L-PEI and B-PEI 
polyplexes (3.1), transfection efficiency of purified melittin-PEI polyplexes was 
reduced compared to non-purified polyplexes, indicating that the removal of both free 
PEI and free melittin-PEI reduces the transfection activity of polyplexes. However, 
purified polyplexes with melittin (CMA-3-PEI) still mediated 3-fold (HUH-7) and 50-
fold (Renca-EGFR) higher levels of luciferase activity compared to purified PEI 
polyplexes without melittin. Since purified polyplexes remained stable over 7 days at 
4°C, such polyplexes were analyzed for transfection activity in HUH-7 and Renca-
EGFR cells to estimate whether activity was retained after storage (Fig. 29). It is 
important to note that the stored purified polyplexes with CMA-3-PEI were still 10-fold 
more efficient than stored purified polyplexes without melittin. 
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Fig. 29 Reporter gene expression of stored purified polyplexes. HUH-7 (A) and Renca-EGFR cells (B) 
were transfected with indicated concentrations of purified (‘P’) PEG-shielded and EGFR-targeted PEI 
or CMA-3-PEI polyplexes which have been stored over 7 days at 4°C. Luciferase activity is presented 
as mean values + SD of triplicates. 
In addition, the effect of PEG-shielding and purification on the overall toxicity of these 
particles was analyzed. Non-shielded and shielded, EGFR-targeted polyplexes were 
prepared with B-PEI and CMA-3-PEI, and these complexes were further purified by 
SEC. HUH-7 cells were transfected with purified and non-purified polyplexes, and 
metabolic activity of cells was determined 24 h after transfection (Fig. 30). Metabolic 
activity of cells transfected with shielded and receptor-targeted polyplexes was 
approximately 20 % higher compared to cells transfected with non-shielded 
polyplexes indicating that shielding indeed reduced toxicity of polyplexes. Toxicity of 
both non-shielded and shielded polyplexes was further reduced after removal of free 
polycations by SEC-purification. Metabolic activity after transfection with purified, 
non-shielded polyplexes was 77 % (PEI) and 104 % (CMA-3-PEI) compared to 49 % 
(PEI) and 57 % (CMA-3-PEI) when using non-purified polyplexes. In the case of 
PEG-shielded polyplexes metabolic activity after transfection with purified polyplexes 
was 101 % (PEI) and 88 % (CMA-3-PEI), which was 25 % (PEI) and 12 % (CMA-3-
PEI) higher than after transfection with non-purified shielded polyplexes.  
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Fig. 30 Metabolic activity after transfection with purified polyplexes. HUH-7 cells were transfected with 
non-shielded polyplexes (left bars) or polyplexes shielded with PEG-PEI25 (‘PEG’) and targeted with 
EGF-PEG-PEI25 (‘EGF’) (right bars). ‘N’: non-purified polyplexes; ‘P’: purified polyplexes. Metabolic 
activity is presented as mean values + SD of triplicates. 
In summary, melittin or melittin analogs with acidic modifications improved the 
transfection efficiency of shielded and targeted polyplexes with a near neutral zeta 
potential. The best effects were obtained using CMA-3-PEI, the conjugate which 
exposed the highest lytic activity at endosomal pH 5. After removal of free melittin-
PEI by SEC such purified shielded and targeted polyplexes were still more efficient in 
gene transfer than polyplexes without melittin suggesting that complex-bound 
melittin-PEI indeed improved intracellular delivery of purified polyplexes. Notably, 
purification further reduced toxicity of shielded EGFR-targeted complexes with 
melittin resulting in a gene delivery system that was non-toxic, even at high DNA 
concentrations of 4 µg/ml. 
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4 Discussion 
4.1 Purification of PEI polyplexes highlights the role of free PEI 
PEI is one of the most efficient nonviral gene transfer agents for transfections in cell 
culture and in vivo. However, pronounced cellular toxicity of PEI and severe systemic 
side effects limit the use of PEI polyplexes for gene transfer in vivo. In addition, it has 
been shown previously that standard PEI polyplexes generated at charge ratios 
above N/P 5 contain up to 80 % of unbound PEI (55;56), and that cellular toxicity of 
polyplexes directly correlates with increased N/P ratios (57;58). These results 
suggest that toxicity is at least partially attributed to free PEI. Therefore, a major aim 
of the present work was to develop an efficient method to purify polyplexes from 
excess PEI. Recently, a method based on ultrafiltration was used in order to remove 
unbound PEI (55). However, removal of free PEI using this method was incomplete 
(55). The easy and efficient method based on SEC developed in this thesis now 
allows complete removal of excess PEI from both L-PEI and B-PEI polyplexes (3.1). 
The applied SEC-column was pre-conditioned with PEI which reduced unspecific 
binding of PEI polyplexes and highly improved polyplexes recovery yielding in up to 
80 % recovery based on analysis of complexed DNA. Independent from the initial 
N/P ratio used for complex formation, small purified polyplexes (< 200 nm) were 
obtained with a final N/P ratio of 2.5 (Table 1). At this N/P ratio complete retention of 
plasmid DNA was observed in agarose gel shift assays, whereas complexes were 
not fully retarded at N/P ratios below 2.5 (data not shown). This indicated that at N/P 
2.5 all DNA phosphate residues were just saturated with positively charged PEI 
nitrogens. Excess free PEI is not present at this low N/P ratio. Such small polyplexes 
of N/P 2.5, however, could not be generated directly, since preparation of polyplexes 
at an N/P ratio ≤ 3 resulted in large aggregated particles (> 300 nm).  
Both physical parameters (size and surface charge) of polyplexes (Table 1) and their 
biological activity did not change after SEC. Most importantly, the purified PEI 
complexes allowed to verify that i) free PEI was indeed the major cause of toxicity of 
PEI polyplexes with high N/P-ratios, and ii) nevertheless free PEI was apparently an 
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essential factor for intracellular gene delivery thereby enhancing transfection 
efficiency. In vitro transfection with purified polyplexes was overall efficient but 
notably less toxic compared to formulations containing free PEI. Moreover, when 
using high DNA concentrations, purified L-PEI polyplexes were even more efficient in 
reporter gene expression than particles with free PEI. Purified polyplexes led to 
approximately 30-fold higher levels of luciferase activity compared to non-purified 
polyplexes (Fig. 7A right). This enhanced transfection efficiency was largely 
attributed to the lower toxicity of purified particles, since more transfected cells 
survived in the absence of excess PEI. However, luciferase activity normalized to the 
number of surviving cells (Fig. 8) was still five-fold higher for purified polyplexes than 
for non-purified polyplexes when using high DNA doses (Fig. 7A right). This suggests 
that the lower toxicity of purified polyplexes is not the only reason for the observed 
differences in transfection activity. Reduced toxicity of purified particles was obviously 
due to the removal of free PEI, since the addition of free PEI (equivalent to the 
amount of PEI removed from the polyplex solution by SEC) restored the initial level of 
toxicity. 
At low DNA concentrations, polyplexes without free PEI were less efficient in gene 
transfer. Reduced efficiency of purified polyplexes at low DNA concentrations was 
also observed in long-term transfection experiments where reporter gene expression 
was evaluated 48 h or 72 h after transfection (Fig. 9). Similar observations were 
obtained with aggregated polyplexes, although in this case the presence of free PEI 
had less impact on the transfection efficiency (Fig. 10). Results showing that the 
transfection efficiency with PEI polyplexes significantly increases with rising N/P 
ratios (5 or higher) (15;80), where a rising amount of PEI is free in solution, further 
strengthened the evidence that free PEI has an important impact on the efficiency of 
gene delivery at the cellular level. Transfection experiments with purified polyplexes 
allowed clarifying the role of free PEI in more detail. 
Important steps during transfection are membrane association of polyplexes followed 
by endocytosis, endosomal release, nuclear trafficking, nuclear import of DNA, and 
finally transcription of DNA. Each of these steps can be potentially influenced by PEI. 
To investigate whether PEI influences the transfection process at a particular step 
during transfection, time course experiments with and without free PEI were 
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performed. Surprisingly, flow cytometry indicated an increased cellular association of 
purified polyplexes, whereas the presence of free PEI reduced such association 
(Table 2). It is therefore concluded that similar to receptor competition free PEI 
competes with PEI polyplexes for cellular association. Obviously, cellular association 
does not account for reduced gene expression of purified polyplexes at low 
concentrations of DNA. Since enhanced cellular association of purified polyplexes did 
not result in enhanced toxicity, there was additional evidence that toxicity was 
primarily attributed to free PEI but not to the total amount of polyplex interacting with 
the cell. 
Endocytosis of polyplexes is induced soon after cellular association. Microscopic 
experiments showed that some polyplexes are already internalized 30 min after 
transfection, and endocytosis is believed to be accomplished 4 h after transfection 
(81). Transfection experiments with purified polyplexes were performed and free PEI 
was added at different time points. Since the addition of free PEI 4 h after 
transfection led to the strongest enhancement of gene expression, free PEI was 
obviously not required for cellular internalization of polyplexes (Fig. 11). It is therefore 
likely that free PEI rather contributes to endosomal release or any process thereafter. 
In a similar time course experiment confocal live cell imaging showed that free PEI 
added either simultaneously or 4 h post-transfection with purified polyplexes ended 
up in intracellular vesicles that contained both compounds (Fig. 12). From these 
findings the increase in reporter gene expression observed with free PEI added after 
transfection can be explained as follows: purified polyplexes mediate increased 
cellular association of plasmid DNA and are subsequently internalized into 
endosomes. PEI added afterwards is also internalized into endosomes, and these 
vesicles containing PEI alone merge with vesicles containing polyplexes. The free 
PEI now promotes the release of polyplexes from the endosomes. The positive effect 
of adding free PEI to purified polyplexes indicates that a minimum amount of PEI is 
necessary to achieve the proton sponge effect, which has been proposed as the 
major mechanism of endosomal release of PEI polyplexes (19;82). A sufficient 
amount of PEI to achieve enhanced intracellular delivery can also be accomplished 
by either using high N/P ratios (83) or large aggregated polyplexes (19;20). The 
pivotal role of PEI for endosomal release was confirmed by recent data showing that 
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both free and complexed PEI contribute to the proton sponge mechanism: both lead 
to accumulation of chloride in vesicles and buffering of vesicular pH (41). Free PEI 
can also have an impact on gene delivery when added to other polyplexes with poor 
endosomal escape, e.g. polylysine (PLL) polyplexes (82): the reporter gene 
expression of PLL polyplexes was increased 10-fold in the presence of free PEI. 
These data demonstrate that free PEI on the one hand causes pronounced toxicity 
but on the other hand significantly enhances gene expression. Since toxicity is a 
major concern also for the applicability of PEI polyplexes in vivo, purification from 
excess PEI is a very reasonable step to improve the vector system. Minimizing the 
total amount of PEI using purified polyplexes is advisable, also because long term 
toxicity of PEI is unknown. In addition, the availability of well defined gene transfer 
formulations with low toxicity is a vital precondition for the further development of 
gene therapeutic strategies based on synthetic carriers, and purification methods as 
the one developed in this thesis will help to fulfill these requirements. 
Nevertheless, endosomal release of polyplexes remains a key issue that needs to be 
further improved. The desired endosomal release activity of toxic free PEI in 
polyplexes therefore must be replaced by alternative agents that are stably integrated 
into the complex. The membrane active peptide melittin was of particular interest for 
this purpose, because this peptide displayed pronounced membrane destabilizing 
activity and successfully enhanced gene transfer with lipoplexes (47) and PEI 
polyplexes (48;49). 
4.2 C- versus N-mel-PEI: the site of linkage strongly influences the 
biological activity  
Melittin is the major peptide component of the venom of the honey bee Apis melifera 
cerana (84) and belongs to the class of pore-forming membrane active peptides. 
Incorporation of membrane active peptides into nonviral vectors is believed to 
enhance endosomal release by destabilization of the endosomal membrane after 
complex internalization (43). 
For stable incorporation of melittin into vectors, the peptide has to be covalently 
attached to a carrier which strongly binds to DNA, such as PEI. It has been shown 
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previously that PEI bound to the N-terminus of all-(L)-melittin enhanced gene delivery 
with PEI polyplexes (48;49). However, for systemic applicability, conjugates 
containing non-immunogenic all-(D)-peptides would be desirable. Here, transfection 
experiments with two melittin-PEI conjugates, where B-PEI was attached to the N-
terminus of all-(L) or all-(D)-melittin, demonstrated that both conjugates equally 
enhanced luciferase expression and EGFP-expression compared to B-PEI 
polyplexes without melittin (Fig. 14). Hence, the capacity to destabilize endosomal 
membranes is obviously independent of the peptide’s enantiomeric configuration 
which is in agreement with results showing that all-(D) and all-(L)-melittin expose 
similar hemolytic and antibacterial activities (61;62).  
To generate improved non-immunogenic all-(D)-melittin PEI conjugates, both the C-
terminus and the N-terminus of melittin may be considered for covalent binding to 
PEI. The site of linkage, however, might influence melittin’s membrane destabilizing 
activity and its capacity to enhance gene transfer. To determine which site of linkage 
leads to the most potent melittin-PEI conjugate, B-PEI was covalently attached to the 
C-terminus (C-mel-PEI) or the N-terminus of melittin (N-mel-PEI), and the resulting 
conjugates were tested in cell culture.  
Size and surface charge of melittin-PEI polyplexes and B-PEI polyplexes without 
melittin were similar. Reporter gene expression, however, strongly depends on the 
composition of the applied polyplexes. Transfection of different tumor cell lines and of 
slowly dividing PEC cells demonstrated that N-mel-PEI was overall the most efficient 
conjugate for gene delivery. N-mel-PEI polyplexes mediated up to 160-fold higher 
levels of luciferase activity compared to B-PEI polyplexes (Fig. 15B), and the 
percentage of EGFP-positive cells was as high as 42 % compared to only 11 % 
EGFP positive cells achieved with B-PEI polyplexes (Fig. 16). Polyplexes of C-mel-
PEI also improved reporter gene expression compared to B-PEI polyplexes. 
However, C-mel-PEI was less efficient in transfection than N-mel-PEI. Analysis of the 
metabolic activity of transfected cells showed that N-mel-PEI and B-PEI polyplexes 
exposed overall low toxicity at all DNA concentrations tested (Fig. 18); metabolic 
activity was maintained above 75 % compared to untransfected control cells. In 
contrast, metabolic activity was reduced to as low as 2 % after transfection with C-
mel-PEI polyplexes at 4 µg/ml DNA (Fig. 18). This toxicity was most likely due to lysis 
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of the plasma membrane which was not observed with B-PEI or N-mel-PEI 
polyplexes (Fig. 19). Video fluorescence microscopy of transfected HeLa cells 
demonstrated that C-mel-PEI polyplexes at 4 µg/ml DNA induced immediate cell 
membrane destabilization resulting in membrane blebbing and cell lysis (Fig. 20). 
Apparently, the capacity of C-mel-PEI polyplexes to induce cell lysis was due to the 
pronounced membrane destabilizing activity of C-mel-PEI at neutral pH. Membrane 
lysis experiments with erythrocytes at pH 7 showed that PEI conjugated to the C-
terminus of melittin strongly enhanced lysis compared to free melittin, whereas PEI 
attached to the N-terminus of melittin did not improve lytic activity of the bound 
peptide (Fig. 21). Since C-mel-PEI and N-mel-PEI carry the same melittin to PEI 
ratio, the observed differences in erythrocyte lysis at pH 7 are most likely due to the 
different site of melittin linkage to PEI.  
The high impact of linkage-site on the membrane destabilizing activity of melittin may 
be explained by the lysis mechanism that was proposed for melittin (67;85): in a first 
step the cationic peptide adsorbs to the membrane bilayer predominantly by 
electrostatic interactions with negatively charged lipid headgroups. Membrane 
association is probably improved when the peptide is bound to the polycation PEI 
because of enhanced charge interactions with the negatively charged membrane. 
The orientation of melittin relative to the bilayer depends on the peptide to lipid 
concentration (Fig. 31).  
Fig. 31 Orientation of membrane-bound melittin. At low peptide to lipid ratios melittin is oriented 
parallel to the membrane bilayer. Insertion of the N-terminus of melittin (red) into the lipophilic core of 
the membrane occurs at higher peptide to lipid ratios, whereas the cationic C-terminus (blue) anchors 
the peptide at the membrane interface. Membrane insertion results in water influx and bilayer 
perturbation. 
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At low concentrations, melittin is bound parallel to the bilayer and is embedded within 
the lipid headgroups. With an increase in peptide to lipid concentration, the N-
terminus of melittin inserts into the bilayer (65;86), provided that the N-terminus is 
free as in the case of natural melittin or C-mel-PEI (but not in the case of N-mel-PEI). 
The cationic C-terminus does not insert but serves as membrane anchor. There is a 
dynamic equilibrium between interfacially adsorbed and inserted melittin peptides 
(87;88). Inserted melittin favors water penetration into the bilayer due to partial 
protonation of the N-terminus and the positive charge at lysine-7 (65;89). Water 
penetration into the hydrophobic core of the bilayer results in membrane 
destabilization. In the case of C-mel-PEI the conjugated polycation can further 
improve membrane anchoring of the C-terminus thereby stabilizing the membrane 
inserted state of the peptide (Fig. 32). In addition, PEI also bears the capacity to 
destabilize membranes, although its potential to induce e.g. erythrocyte lysis is far 
lower than that of melittin or melittin-PEI conjugates. The observed high lytic activity 
of C-mel-PEI at pH 7 may therefore be due to improved association and insertion of 
melittin followed by membrane perturbation which is synergistically enhanced by the 
destabilizing effect of the attached polycation PEI.  
Fig. 32 Orientation of C-mel-PEI and N-mel-PEI in membrane bilayers. Since the N-terminus of C-mel-
PEI is free, the peptide moiety (red) can insert into the membrane bilayer. PEI (yellow) at the C-
terminus of melittin (blue) can improve membrane anchoring thereby stabilizing the membrane 
inserted state of melittin. Inserted melittin favors water influx into the bilayer which results in 
membrane perturbation and destabilization. In contrast, PEI covalently attached to the N-terminus of 
melittin (N-mel-PEI) prevents membrane insertion and the melittin moiety is supposed to be 
associated parallel to the bilayer. 
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In contrast, N-mel-PEI is supposed to induce lysis by an alternative mechanism, 
since membrane insertion of the N-terminus of melittin is sterically hindered when the 
bulky polycation is attached (Fig. 32). Free melittin has the capacity to lyse 
membranes by formation of transmembrane ‘toroidal’ pores according to the carpet 
or toroidal model which was first described for magainin-induced pores (90;91). 
Toroidal pore formation is induced when the peptide to lipid ratio further increases 
above the threshold necessary for membrane insertion. Although different groups 
could demonstrate that melittin inserts into membrane bilayers (65;86;92), it is not 
clear whether this is an intermediate step required for pore formation. In fact, a 
sufficient high density of peptides bound parallel to and embedded into the bilayer 
may trigger enhanced lipid curvature strain which destabilizes the bilayer without 
vertical peptide insertion (43). Furthermore, inside the toroidal pore the peptide is not 
inserted into the bilayer. After membrane disintegration, the pore is lined by the lipid 
monolayer, which bends continuously from the top to the bottom in the fashion of a 
toroidal hole, and the peptides are associated to the lipid headgroups (Fig. 33). 
Fig. 33 Toroidal pore formation by melittin. With an increase in membrane-bound melittin above a 
certain threshold concentration, melittin induces toroidal pores. Membrane insertion of melittin might 
be an intermediate step during pore formation. The toroidal pore is formed by both the lipid monolayer 
(dark layers) and the peptides (red cylinders with blue cationic C-terminal region) which are associated 
to the lipid headgroups. Adapted from Yang et al. (67) 
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In principle, both C-mel-PEI and N-mel-PEI should have the capacity to form toroidal 
pores above a certain peptide to lipid concentration. N-mel-PEI, however, may even 
better associate parallel to the membrane than C-mel-PEI because N-mel-PEI bears 
positive charges at the C-terminus of melittin (Lys21-Arg22-Lys23-Arg24) and at the 
N-terminus due to conjugated PEI (Fig. 32). In contrast, C-mel-PEI accumulates 
positive charges at the C-terminus only. Therefore, N-mel-PEI may be the more 
potent conjugate for pore formation according to the toroidal pore model, but C-mel-
PEI can already destabilize membranes at lower peptide to lipid concentrations due 
to enhanced insertion into the lipid bilayer followed by water influx and membrane 
perturbation. 
The proposed models for the lysis mechanisms of melittin-PEI conjugates help to 
explain the pronounced membrane destabilizing activity of C-mel-PEI at physiological 
pH and the concomitant high toxicity of C-mel-PEI polyplexes at high DNA doses. 
The pronounced toxicity also partly explains the reduced transfection efficiency of C-
mel-PEI polyplexes compared to N-mel-PEI polyplexes at elevated DNA doses. 
However, C-mel-PEI polyplexes are also less efficient than N-mel-PEI polyplexes at 
low, non-toxic DNA doses. Therefore, toxicity cannot be the only reason for the 
reduced transfection efficiency of C-mel-PEI polyplexes. 
Interestingly, evaluation of the membrane destabilizing activity at endosomal pH 5 
using erythrocytes, PC-liposomes and HeLa cells demonstrated that C-mel-PEI was 
significantly less lytic than N-mel-PEI at pH 5. This result was independent of the type 
of membrane used for the lysis assays and in striking contrast to the observed high 
lytic activity of C-mel-PEI at neutral pH.  
The inverse lytic activity of the two melittin-conjugates at pH 5 and pH 7 may reflect a 
pH-dependent change in the dominating lysis mechanism of the C-mel-PEI 
conjugate. Enhanced protonation of the lipid membrane and melittin might alter their 
mode of interaction. For example, loss of negative charges of the lipid membrane 
presumably reduces the lipid-bound concentration of the cationic melittin peptide, 
even below the peptide to lipid concentration required for inserting the N-terminus of 
melittin into the bilayer. This is also consistent with the known lower lytic activity of 
free melittin at pH 5 as compared to pH 7 (93). In addition, at acidic pH the N-
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terminus of melittin in C-mel-PEI is highly protonated and therefore more hydrophilic. 
This could reduce insertion of the N-terminus into the hydrophobic core of the bilayer 
membrane. As a consequence, the peptide moiety would be mainly bound parallel to 
the membrane at acidic pH resulting in membrane destabilization according to the 
toroidal pore model similar to N-mel-PEI. Since N-mel-PEI is supposed to be more 
potent in parallel membrane association and in inducing toroidal pores than C-mel-
PEI (see above) this would explain the higher lytic activity of N-mel-PEI compared to 
C-mel-PEI at pH 5.  
The high lytic activity of N-mel-PEI compared to C-mel-PEI at pH 5 obviously 
promotes better endosomal escape of N-mel-PEI polyplexes, and this can explain the 
higher transfection efficiency of N-mel-PEI polyplexes compared to C-mel-PEI 
polyplexes. This apparent correlation of gene transfer efficiency with lytic activity at 
pH 5 was also found with other membrane-active peptides, including influenza virus 
haemagglutinin fusion peptides (43;93;94).  
In summary, the site of melittin-linkage to PEI significantly affects the membrane 
destabilizing activities of the resulting conjugates and this has a strong impact on the 
biological activities of the corresponding polyplexes. C-mel-PEI was highly lytic at 
neutral pH and, therefore, elevated doses of C-mel-PEI polyplexes induced high 
toxicity. In contrast, N-mel-PEI was less lytic at neutral pH but retained higher lytic 
activity than C-mel-PEI at endosomal pH 5. This apparently promotes better 
endosomal release of N-mel-PEI polyplexes resulting in efficient gene delivery in 
different cell types.  
Although N-mel-PEI polyplexes were more effective in gene transfer than C-mel-PEI 
polyplexes, C-mel-PEI was regarded as a more potent template to generate 
improved endosomolytic melittin-conjugates because of its higher capacity to 
destabilize membranes already at low peptide to lipid ratios. Therefore, PEI was 
attached to the C-terminus of new melittin analogs which were modified with acidic 
residues to improve the lytic activity at endosomal pH.  
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4.3 Improved melittin-PEI conjugates enhance gene transfer 
In contrast to C-mel-PEI, the new melittin-PEI conjugates should be primarily active 
at acidic pH to trigger enhanced membrane destabilization within acidic vesicles such 
as endosomes. According to the literature, the positive charges at the C-terminus 
(KRKR21-24) for membrane anchoring and at the amino terminal NH2-group for 
membrane perturbation are important structural features for lytic melittin analogs 
(69;70). In order to shift the optimum of melittin’s membrane lytic activity towards 
endosomal pH 5, glutamic acidic residues or histidine residues were introduced into 
the peptide’s sequence at these important structural domains (Table 3). In the 
melittin analogs CMA-1 and CMA-4 two glutamic acid residues were added to the N-
terminus of melittin. In CMA-2 and CMA-4 the cationic cluster KRKR21-24 at the C-
terminus of melittin was replaced by histidine residues which are uncharged at 
physiological pH and positively charged at acidic pH. In CMA-2 and CMA-3 two 
glutamine residues next to the cationic cluster region were replaced by two glutamic 
acid residues introducing negative charges at physiological pH. In all melittin 
analogs, the altered or inserted residues become protonated at acidic pH only, 
thereby restoring the required positive charges at the C-terminus and the N-terminus 
to induce membrane destabilization. In contrast, at neutral pH these analogs lack 
sufficient positive charges which should prevent the lytic activity. 
Synthesis of C-terminal-linked CMA-PEI conjugates was performed as described for 
melittin-PEI conjugates. Recovery rates after conjugate purification, however, were 
low (as low as 7 % for CMA-2-PEI) which was probably due to unspecific and 
irreversible binding of conjugates to the cation-exchange column and/or to the 
membrane of the stirred ultrafiltration cell that was used to concentrate and desalt the 
conjugates after purification. Recovery rates were significantly improved when 
conjugates were purified by SEC using a column that was pre-conditioned with PEI to 
reduce unspecific binding. Since the conjugate concentration in the eluted fractions 
was high enough (PEI concentration ≥ 0.4 mg/ml) further concentration was not 
necessary, and after subsequent dialysis recovery based on analysis of PEI was 
50 % for CMA-2-PEI and 30 % for CMA-3-PEI compared to 7 % and 15 %, 
respectively, following the cation-exchange protocol.  
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Membrane lysis assays at pH 5 and pH 7 (Fig. 23, Fig. 24) demonstrated that 
insertion of acidic residues next to the C-terminal membrane anchoring domain of 
melittin indeed resulted in melittin-PEI conjugates (CMA-2-PEI and CMA-3-PEI) 
which displayed significantly improved lytic activity at endosomal pH.  
Sequence modifications that included both the C-terminus and the N-terminus 
resulted in the rather non-lytic conjugate CMA-4-PEI. Obviously, this kind of 
modification interfered too strongly with the peptide’s conformation and/or membrane 
interaction thereby inhibiting membrane lysis. The conjugate CMA-1-PEI, where 
melittin was only modified at the N-terminus, retained high lytic activity at neutral pH. 
At acidic pH, however, CMA-1-PEI exhibited low lytic activity similar to C-mel-PEI. 
Only on HeLa cell membranes, CMA-1-PEI exposed higher membrane destabilizing 
activity than C-mel-PEI at pH 5. Overall, CMA-1-PEI did not fulfill the requirements of 
an optimized conjugate with improved lytic activity at endosomal pH 5.  
Notably, both conjugates that were modified only at the C-terminus of melittin (CMA-
2-PEI and CMA-3-PEI) displayed the desired high lytic activity at pH 5 both on 
erythrocytes and HeLa cells (Fig. 23). The membrane destabilizing activities of CMA-
2-PEI and CMA-3-PEI were approximately 7- to 10-fold higher compared to C-mel-
PEI. Surprisingly, CMA-2-PEI and CMA-3-PEI were also about 2-fold more lytic than 
C-mel-PEI at neutral pH (Fig. 24). Since CMA-2-PEI and CMA-3-PEI exposed similar 
lytic activities both at pH 5 and pH 7, the higher membrane destabilizing activities 
were obviously mainly attributed to the exchange of glutamine by glutamic acid 
residues, whereas replacement of KRKR21-24 by histidine had no further impact on 
their lytic activities. It is important to note that the improved lytic activities of CMA-2-
PEI and CMA-3-PEI compared to C-mel-PEI were only observed with the PEI 
conjugates. The free peptides CMA-2 and CMA-3 showed significant lytic activities at 
pH 5 (CMA-2, CMA-3) and pH 7 (CMA-3), but were overall less lytic than free melittin 
both at pH 5 and pH 7 (data not shown). Lysis experiments with the conjugate C-mel-
PEI compared to free melittin have already demonstrated that PEI bound to the C-
terminus of melittin enhances the lytic activity of the peptide at pH 7 (3.2.6). These 
results highlight that conjugation to PEI has a strong impact on the overall membrane 
destabilizing activity of the melittin peptides and that activities of the isolated peptide 
moieties do not necessarily correlate with activities after conjugation. The enhancing 
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effect of conjugated PEI may also explain why additional replacement of the 
membrane anchoring domain KRKR21-24 by histidine residues had no further effect on 
the membrane destabilizing activities, because within these C-terminal conjugates 
the polycation PEI functions as membrane anchor. The enhanced lytic activities of 
CMA-2-PEI and CMA-3-PEI compared to C-mel-PEI were obviously due to the 
negatively charged glutamic acid residues that were introduced at the C-terminus. 
The reason for this enhancement is currently unknown, as the effect is independent 
of pH or the peptide’s own lytic activity. It is proposed that the negative glutamic acid 
charges facilitate changes within the conformation and structural orientation of the 
peptide within the PEI polycation conjugate which increase the synergistic 
membrane-destabilizing effect of PEI.  
In excellent agreement with results obtained with unmodified melittin-PEI conjugates 
(3.2) and other membrane active peptides used in gene transfer (43;93;94), the lytic 
activities of the CMA-PEI conjugates at pH 5 were found to correlate with their gene 
transfer activities (Fig. 25). The non-lytic conjugate CMA-4-PEI was ineffective in 
gene delivery. CMA-1-PEI exposed similar low lytic activity at pH 5 as C-mel-PEI 
and, consequently, CMA-1-PEI polyplexes mediated similar levels of luciferase 
activity compared to C-mel-PEI polyplexes. Most importantly, CMA-2-PEI and CMA-
3-PEI, which displayed the highest lytic activity at pH 5, were indeed the most 
efficient in gene transfer in all four cell lines tested. Transfection efficiency of CMA-2-
PEI and CMA-3-PEI polyplexes was up to 10-fold higher compared to C-mel-PEI 
polyplexes. This highlights that gene transfer activity of C-terminal conjugated 
melittin-PEI polyplexes can be optimized by designing melittin analog conjugates with 
improved membrane destabilizing activity at endosomal pH 5.  
On the other hand toxicity assays revealed that lytic activity at neutral pH correlated 
with toxicity of the corresponding polyplexes as already observed for C-mel-PEI 
polyplexes (3.2). The conjugates C-mel-PEI, CMA-2-PEI and CMA-3-PEI were all 
highly lytic at pH 7, and these polyplexes mediated pronounced toxic effects at 
elevated DNA concentrations (≥ 4 µg/ml) (Fig. 26). As visualized with C-mel-PEI 
polyplexes by video fluorescence microscopy (3.2.5), toxicity was likely related to 
partial destabilization of the plasma membrane resulting in cell lysis and cell death. 
Analysis of the metabolic activity of cells 24 h after transfection revealed that 
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complexes of C-mel-PEI induced the strongest reduction of metabolic activity, 
followed by CMA-3-PEI and CMA-2-PEI polyplexes (Fig. 26). In contrast, CMA-1-PEI 
and CMA-4-PEI were less lytic at pH 7, and these polyplexes as well as PEI 
polyplexes without melittin exposed lower toxicity.  
In conclusion, the membrane destabilizing activity of melittin-PEI conjugates at 
endosomal pH 5 correlates with their capacity to induce endosomal escape and 
hence their efficiency to enhance gene transfer. Improved endosomolytic melittin-PEI 
conjugates were obtained by sequence modification of melittin with acidic residues. 
These conjugates displayed significantly higher membrane destabilizing activity at 
pH 5 compared to the C-terminal conjugate with natural melittin. Polyplexes that were 
generated with these optimized conjugates were up to 10-fold more efficient in 
transfection compared to polyplexes with unmodified melittin-PEI conjugates. 
However, transfection with these improved endosomolytic polyplexes was associated 
with significant toxicity at high DNA doses. Similar to C-mel-PEI polyplexes, toxicity 
was likely related to the high lytic activity at pH 7 resulting in plasma membrane 
disruption and death of transfected cells. Despite these toxic side effects, the 
endosomolytic conjugates CMA-2-PEI and CMA-3-PEI were promising candidates for 
the development of multifunctional artificial viruses. 
4.4 Towards artificial viruses 
Regarding the development of improved artificial viruses which are efficient and safe 
also for potential in vivo administration, three key issues had to be tackled. Firstly, 
the most efficient melittin-PEI conjugates had to be incorporated into surface-
shielded and receptor-targeted PEI polyplexes. Secondly, transfection experiments 
with purified particles had to prove whether complex-bound endosomolytic domains 
like melittin-PEI conjugates were able to enhance gene delivery of such particles 
lacking free PEI conjugates. Thirdly, since toxicity was a major concern of polyplexes 
containing melittin-PEI conjugates, it was of great importance to evaluate whether the 
resulting purified particles would display an improved toxicity profile. 
In vitro transfection experiments with melittin-PEI conjugates were performed with 
positively charged polyplexes. After systemic administration of such particles, 
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however, the positive surface charge mediates nonspecific interactions with e.g. 
blood components or non-target cells which prevent specific gene transfer and can 
cause significant toxicity (22). Therefore, polyplexes need to be shielded with 
hydrophilic polymers like PEG to prevent such unspecific interactions (21;23). Two 
different shielding conjugates were recently used to successfully shield PEI 
polyplexes, with PEG covalently attached to L-PEI (PEG-PEI22) for shielding L-PEI 
polyplexes, or PEG conjugated to B-PEI (PEG-PEI25) for shielding B-PEI polyplexes 
(71). In this thesis, both shielding conjugates were tested for the surface shielding of 
B-PEI polyplexes. Interestingly, shielding with PEG-PEI22 was obviously insufficient, 
since the zeta potential of B-PEI polyplexes containing up to 20 % of PEG-PEI22 
remained positive (above +13 mV, Table 4). Effective shielding of B-PEI polyplexes 
was, however, achieved with PEG-PEI25. Although the amount of PEG conjugated to 
B-PEI was 2-fold lower than in the PEG-PEI22 conjugate, a ratio of 10 % PEG-PEI25 
was sufficient to generate small particles (< 100 nm) with a near neutral zeta potential 
(Table 4). The different shielding capacities of PEG-PEI22 compared to PEG-PEI25 
might be due to the higher DNA binding affinity of B-PEI compared to L-PEI (Julia 
Klöckner, unpublished results). Polyplexes that are generated with a mixture of L-PEI 
and B-PEI will therefore contain higher amounts of B-PEI compared to L-PEI. 
Accordingly, the degree of PEG conjugate bound to DNA in the presence of excess 
B-PEI will be significantly higher with PEG-PEI25 than with PEG-PEI22. This can 
explain effective shielding with PEG-PEI25 in contrast to PEG-PEI22. 
Since PEG-shielding alone reduces non-specific interactions but also desired 
interactions with the target cells, targeting ligands have to be incorporated into the 
polyplexes. Recently, successful targeting of PEI polyplexes towards the EGF-
receptor, which is highly overexpressed on several tumor cell lines (e.g. HUH-7 
human hepatoma cells) (79), was achieved using the ligand EGF linked to B-PEI via 
a PEG-spacer (EGF-PEG-PEI25) (28). Here, a similar conjugate was incorporated 
into PEG-PEI25-shielded B-PEI or melittin-PEI polyplexes, resulting in particles that 
were still small with a near neutral zeta potential (Table 4C).  
Transfection experiments in EGFR-rich HUH-7 and Renca-EGFR cells demonstrated 
that melittin-PEI conjugates not only enhanced gene delivery with positively charged 
polyplexes but also significantly improved transfection efficiency of surface-shielded 
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polyplexes (Fig. 27). The gene transfer activity again correlated with the lytic activity 
of the incorporated conjugate at pH 5. When using positively charged polyplexes the 
three most efficient melittin-PEI conjugates were N-mel-PEI and the melittin analog 
conjugates CMA-2-PEI and CMA-3-PEI, where PEI was linked to the peptide’s C-
terminus. These three conjugates all exposed high lytic activity at endosomal pH 5 
(Fig. 22, Fig. 23). PEG-shielded and EGFR-targeted polyplexes generated with these 
endosomolytic melittin-PEI conjugates significantly enhanced gene delivery 
compared to PEG-shielded polyplexes without melittin. The best results were 
obtained with CMA-3-PEI which mediated up to 70-fold higher levels of luciferase 
activity compared to shielded and targeted B-PEI polyplexes without melittin (Fig. 
27). In contrast, the conjugate C-mel-PEI, with PEI attached to the C-terminus of 
natural melittin exposed low lytic activity at pH 5, and, consequently, C-mel-PEI did 
not improve gene transfer of shielded polyplexes in comparison to shielded PEI 
complexes without melittin.  
It remained to be shown, however, that enhanced transfection efficiency of the best 
endosomolytic melittin-PEI conjugates was attributed to melittin-PEI which was stably 
incorporated into the polyplexes. Therefore, shielded and targeted polyplexes 
containing the most efficient CMA-3-PEI conjugate were purified by SEC to remove 
unbound CMA-3-PEI and then tested for gene transfer activity (Fig. 28). In line with 
the previous results obtained with SEC-purified L-PEI and B-PEI polyplexes (3.1) 
(95), gene transfer efficiency was reduced after the removal of free PEI or CMA-3-
PEI from the shielded polyplexes. Thus, free polycations also have an additive effect 
for the gene transfer efficiency of shielded polyplexes. It is important to note that the 
efficiency of purified shielded polyplexes with the endosomolytic conjugate CMA-3-
PEI was still up to 50-fold higher than that of purified polyplexes without melittin (Fig. 
28). Purified shielded CMA-3-PEI polyplexes also retained high gene transfer activity 
after storage at 4°C for 7 days. The stored polyplexes were stable regarding size and 
zeta potential and mediated about 10-fold higher levels of luciferase activity 
compared to stored purified polyplexes lacking melittin (Fig. 29). The apparent 
storage stability is of great importance regarding the development of a potential 
therapeutic gene delivery system.  
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In vitro analysis of the metabolic activity of cells transfected with PEG-shielded 
polyplexes showed that shielding reduced toxicity of polyplexes (Fig. 30), which is in 
good agreement with previous results obtained by Ogris et al. (23). Most importantly, 
purification from unbound polycations further reduced toxicity resulting in polyplexes 
that were non-toxic even at high DNA doses. Therefore, the final requirement of an 
optimized artificial virus was fulfilled: the incorporation of the improved endosomolytic 
melittin-PEI conjugate CMA-3-PEI into purified shielded and receptor-targeted 
polyplexes significantly enhanced transfection efficiency in comparison to polyplexes 
lacking melittin, and these polyplexes exposed an improved toxicity profile providing 
a vector system that is efficient and safe also for potential in vivo administration.  
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5 Summary 
For the development of improved polyethylenimine (PEI) polyplexes towards ‘artificial 
viruses’ two key issues are i) to improve the toxicity profile of the applied vectors and 
ii) to enhance endosomal release, one of the major barriers to efficient gene transfer 
with PEI polyplexes.  
Nonviral vectors based on PEI usually contain an excess of PEI that is not 
complexed to DNA. Since free PEI contributes to cellular and systemic toxicity 
purification of polyplexes from unbound PEI is highly desirable. In this thesis an easy 
and efficient method based on size exclusion chromatography (SEC) was developed, 
which for the first time allowed complete removal of PEI from PEI polyplexes. 
Moreover, purification of polyplexes enabled to clarify the role of free PEI in gene 
delivery at the cellular level. Most importantly, the removal of unbound PEI 
significantly reduced toxicity of the applied polyplexes. However, purified polyplexes 
without free PEI were less efficient in transfection compared to non-purified 
polyplexes. Mechanistic studies showed that free PEI most likely enhanced 
endosomal release of polyplexes and therefore contributed to efficient gene transfer 
with PEI polyplexes. Nevertheless, the availability of a defined, well-tolerated gene 
transfer formulation is a vital precondition for the further development of nonviral 
gene therapeutics, and a purification method like the one developed in this thesis will 
help to fulfill these requirements.  
To enhance endosomal release of PEI polyplexes, the membrane active peptide 
melittin was incorporated into the vector particles. It has been shown previously that 
PEI bound to the N-terminus of natural all-(L)-melittin (all-(L)-N-mel-PEI) enhanced 
gene delivery with PEI polyplexes. Here, it was demonstrated that transfection 
efficiency of N-mel-PEI is independent of the enantiomeric configuration of the bound 
peptide which allowed the use of non-immunogenic all-(D)-melittin for the generation 
of optimized melittin-PEI conjugates.  
To determine the optimal site of melittin-linkage to PEI, the polycation PEI was 
covalently attached to the N-terminus (N-mel-PEI) or the C-terminus of melittin (C-
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mel-PEI) in all-(D)-configuration. The site of melittin-linkage had a strong impact on 
the membrane destabilizing activities of the resulting melittin-PEI conjugates. C-mel-
PEI was highly lytic at neutral pH and therefore elevated doses of C-mel-PEI 
polyplexes induced high toxicity. In contrast, N-mel-PEI was less lytic at neutral pH 
but retained higher lytic activity than C-mel-PEI at endosomal pH 5. This apparently 
promoted better endosomal release of N-mel-PEI polyplexes resulting in efficient 
gene delivery in different cell lines. The high potency of C-mel-PEI to destabilize 
membranes at neutral pH is presumably due to a reported destabilization mechanism 
proceeding through membrane insertion of the peptide. In contrast, N-mel-PEI is 
supposed to induce lysis by insertion-independent pore formation according to the 
toroidal pore model. Since membrane destabilization by membrane insertion requires 
lower peptide to lipid ratios than destabilization by pore formation, C-mel-PEI was 
considered as the more potent template to generate improved endosomolytic 
melittin-PEI conjugates.  
The new melittin-PEI conjugates should display pronounced lytic activities at 
endosomal pH 5. Therefore, PEI was attached to the C-terminus of melittin analogs 
which were modified with acidic residues. The conjugates with the highest lytic 
activities at endosomal pH 5 were indeed the most efficient in transfection. This 
apparent correlation of gene transfer efficiency with lytic activity at pH 5 was in 
excellent agreement with results obtained with unmodified melittin-PEI conjugates 
and other membrane-active peptides used in gene transfer. 
The most efficient melittin-PEI conjugates were incorporated into surface-shielded 
and receptor-targeted PEI polyplexes, and the resulting particles were further purified 
by SEC to remove unbound toxic polycations. Endosomolytic melittin-PEI conjugates 
stably incorporated into such purified polyplexes significantly enhanced transfection 
efficiency in comparison to polyplexes lacking melittin. Most importantly, these 
polyplexes exposed an improved toxicity profile providing an artificial virus-like vector 
that is efficient and safe also for potential in vivo administration. 
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6 Appendix 
6.1 Abbreviations 
ATP adenosine triphosphate 
B-PEI branched PEI of 25 kDa 
B-PEI-PDP B-PEI modified with pyridyldithio-propionate-linkers 
CMA-PEI PEI covalently attached to the C-terminus of a melittin 
analog 
C-mel melittin with a cysteine residue at the C-terminus 
C-mel-PEI PEI covalently attached to the C-terminus of melittin 
CMV cytomegalovirus 
DID 1,1'-dioctadecyl-3,3,3',3'- tetramethylindodicarbocyanine 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DTT dithiothreitol 
EDTA ethylenediaminetetraacetic acid 
EGF epidermal growth factor 
EGFP Enhanced Green Fluorescent Protein 
EGF-PEG-PEI25 EGF covalently linked to B-PEI of 25 kDa with a 
heterobifunctional 3.4 kDa PEG spacer 
EtBr ethidium bromide 
FCS fetal calf serum 
HBG HEPES-buffered glucose 
HBS HEPES-buffered saline 
HEPES N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) 
K lysine 
L-PEI linear PEI of 22 kDa 
N/P ratio molar ratio of PEI nitrogen to DNA phosphate 
NA numerical aperture  
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N-mel melittin with a cysteine residue at the N-terminus 
N-mel-PEI PEI covalently attached to the N-terminus of melittin 
PBS phosphate-buffered saline 
PC phosphatidylcholine 
pCMVLuc plasmid encoding for luciferase under control of the CMV 
promoter/enhancer 
PEG polyethylene glycol 
pEGFP plasmid encoding for EGFP 
PEG-PEI22 PEG of 20 kDa covalently attached to L-PEI of 22 kDa 
PEG-PEI25 PEG of 20 kDa covalently attached to B-PEI of 25 kDa 
PEI polyethylenimine 
PI propidium iodide 
PLL polylysine 
R arginine 
RLU relative light units 
RNA ribonucleic acid 
RT room temperature 
SCID severe combined immunodeficiency 
SD standard deviation 
SEC size exclusion chromatography 
siRNA small interfering RNA 
SPDP succinimidyl 3-(2-pyridyldithio) propionate 
TNBS trinitrobenzenesulfonic acid 
TNF-α tumor necrosis factor α 
w weight 
Appendix 89 
6.2 Publications 
6.2.1 Original Papers 
Boeckle, S., von Gersdorff, K., van der Piepen, S., Culmsee, C., Wagner, E., and 
Ogris, M. (2004), Purification of polyethylenimine polyplexes highlights the role of 
free polycations in gene transfer, J. Gene Med. 6, 1102-1111 
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press 
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polyplexes, in preparation 
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